The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management

Tulasi Yadati, Tom Houben, Albert Bitorina and Ronit Shiri-Sverdlov *

School of Nutrition & Translational Research Maastricht (NUTRIM), Department of Molecular Genetics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands; t.yadati@maastrichtuniversity.nl (T.Y.); tom.houben@maastrichtuniversity.nl (T.H.); a.bitorina@maastrichtuniversity.nl (A.B.)
* Correspondence: r.sverdlov@maastrichtuniversity.nl; Tel.: +31-43-388-1746; Fax: +31-43-388-4574

Abstract: Cathepsins are the most abundant lysosomal proteases that are mainly found in acidic endo/lysosomal compartments where they play a vital role in intracellular protein degradation, energy metabolism, and immune responses among a host of other functions. The discovery that cathepsins are secreted and remain functionally active outside of the lysosome has caused a paradigm shift. Contemporary research has unraveled many versatile functions of cathepsins in extralysosomal locations including cytosol and extracellular space. Nevertheless, extracellular cathepsins are majorly upregulated in pathological states and are implicated in a wide range of diseases including cancer and cardiovascular diseases. Taking advantage of the differential expression of the cathepsins during pathological conditions, much research is focused on using cathepsins as diagnostic markers and therapeutic targets. A tailored therapeutic approach using selective cathepsin inhibitors is constantly emerging to be safe and efficient. Moreover, recent development of proteomic-based approaches for the identification of novel physiological substrates offers a major opportunity to understand the mechanism of cathepsin action. In this review, we summarize the available evidence regarding the role of cathepsins in health and disease, discuss their potential as biomarkers of disease progression, and shed light on the potential of extracellular cathepsin inhibitors as safe therapeutic tools.

Keywords: lysosomes; cathepsins; translocation; site-specific functions; targeted-drug delivery

1. Introduction

Lysosomes are intracellular membrane-bound organelles characterized by an acidic interior and harbor a variety of hydrolytic enzymes including lipases, proteases and glycosidases that participate in cellular catabolism [1,2]. The functions of most of these enzymes require an acidic lumen, which is maintained by the vacuolar H+ ATPase (V-ATPase), an ATP-driven proton pump located on the lysosomal transmembrane. Lysosomes can fuse with endosomes, phagosomes, autophagosomes and break down both endogenous and exogenous cargo consisting of various biomolecules such as lipids, proteins, polysaccharides, and certain pathogens. Additionally, lysosomes play critical roles in some of the most vital processes such as metabolic signaling, repair of the plasma membrane and nutrient sensing [3–5]. Lysosomes perform this multitude of coordinated events with the help of their enzymes.

Among the variety of enzymes that lysosomes harbor, cathepsins are a family of lysosomal proteases with an astonishingly broad spectrum of functions. Cathepsins help in intracellular house-keeping where

they for example, participate in the antigen processing during immune responses and degrade several proteases and chemokines to maintain cellular homeostasis (reviewed in [6,7]). Mammalian proteases have been classified into 5 different families namely metallo, serine, threonine, aspartic, and cysteine proteases based on the type of amino acid at the active site. All cathepsins fall into three different protease families viz; serine proteases (cathepsins A and G), aspartic proteases (cathepsin D and E) and eleven cysteine cathepsins (cathepsins B, C, F, H, K, L, O, S, V, X, and W) [6,8,9]. Serine proteases constitute up to 31% of total proteases expressed in human body, while cysteine and aspartic proteases make up for 25% and 4% of the total protease population respectively [6,10]. Cathepsins show highest activity in the low pH environment of lysosomes. However, certain cathepsins are also found to be active outside of their optimal pH range of 5 [6,11]. The pH optimum of cathepsin S was found to be 6.5 [12,13]. While cathepsin D shows optimal activity at pH 4, its activity was detected even at pH of 7.4 (although at reduced kinetic rates) [14]. Moreover, cathepsin K and H displayed stable activity at pH 7 [15] indicating their wide range of proteolytic activity. Due to the retained activity far outside the optimal pH range cathepsins have been identified with specific proteolytic functions even outside of the endo/lysosomal system [16,17].

Although cathepsins exhibit some level of similarity in their proteolytic functions in physiological processes, consequences of cathepsin dysfunction are very diverse in terms of clinical symptoms. Deregulated cathepsin synthesis and activity has been associated with several diseases including the metabolic syndrome, cancer and inflammatory neurological diseases (reviewed in [18]). Cathepsins are known to activate and/or degrade several important neuronal proteins, and thus have important roles in neurodegenerative disorders (reviewed in [19,20]). For example, cathepsin D plays an important role in neuronal cell homeostasis whose dysfunction leads to impaired proteolysis of target proteins such as huntingtin, α-synuclein, tau, lipofuscin, apoE resulting in Huntington's and Parkinson's amongst other neurological disorders [20]. In addition to cathepsin D, several cathepsins are associated with inflammatory neurological diseases including Niemann–Pick type C (NPC) disease, neuronal ceroid lipofuscinosis (NCL) and Alzheimer's (reviewed in [21–23]). Cardiovascular disorders such as cardiomyopathy, hypertension, myocardial infarction, atherosclerosis and aortic aneurysms are characterized by extensive extracellular matrix (ECM) degradation and remodeling, one of prime processes mediated by cathepsins (reviewed in [24]). Similarly, in cancer, tumors metastasize by ECM degradation and cathepsins are known to breakdown the constituents of ECM, epithelial membrane and cell–cell junctions facilitating cancer cell migration. Further, cathepsins are involved in growth, invasion, angiogenesis, and therapeutic resistance associated with tumors [25]. Obesity and diabetes are most common metabolic disorders and cathepsins L, S, and K are found to have potential roles in these pathologies (reviewed in [26]). Thus, the range and complexity of biological activities reliant on cathepsins make them a common point of interest in diverse diseases. Importantly, owing to their differential function during physiological and pathological conditions, cathepsins are considered as highly relevant targets for therapeutic intervention in this range of diseases.

This review is divided into four parts. In the first part, we provide a basic overview of cathepsin expression and function within the endo/lysosomal compartments. In the next two parts, we emphasize on the mechanisms leading to the translocation of cathepsins into the cytosol and extracellular milieu respectively. Finally, this review further highlights the prospect of using highly specific, targeted cathepsin inhibitors for clinical implementation in various diseases.

2. Cathepsins in Lysosomes

Cathepsins exhibit similarities in their cellular localization and biosynthesis with some differences in their expression pattern. Of all the lysosomal proteases, cathepsins L, B, and D are the most abundant with their lysosomal concentrations equivalent to 1 mM [27]. Cathepsins B, H, L, C, X, V, and O are ubiquitously expressed while cathepsins K, S, E, and W show cell or tissue-specific expression. Cathepsin K is expressed in the osteoclasts (multinucleated cells of bone) and in epithelial cells. Cathepsins S, E, and W are mainly expressed in immune cells.

2.1. Regulation

Cathepsins undergo transcriptional, translational, post-translational and epigenetic regulation. At transcriptional level, except for cathepsin D all other cathepsins show TATA-independent transcription initiation which defines the transcription initiation site. Cathepsin L, K, C, and B are known to require various transcription factors such as nuclear factor (NF-Y), specificity proteins, Sp1, Sp3 and erythroblast transformation-specific (Ets) family factors for transcription initiation and regulation [28,29]. Cathepsin D is known to be transcriptionally regulated by Peroxisome Proliferator-Activated Receptor γ in dendritic cells [30] and by estrogen in breast cancer cells [31]. Transcript variants for cathepsin B and L have been reported as a result of alternative splicing. These transcripts differ in their mRNA stability and thus are known to be accumulated during tumors [32]. Cathepsin L is found to be translationally regulated by internal ribosomal entry site (IRES) [33]. Cysteine cathepsins are known to also contain CpG islands in their promoter region and thus are epigenetically regulated by methylation [25]. Additionally, cathepsin enzyme activity is regulated by pH and endogenous protein inhibitors such as stefins, cystatins, and kiniogens [8].

2.2. Synthesis

The primary structure of all cathepsins consists of a signal peptide, a propeptide, and a catalytically active mature functional enzyme. Cathepsins are synthesized as preprocathepsins in the endoplasmic reticulum (ER). A N- terminal signal peptide of 20–25 amino acids directs preprocathepsins into the ER lumen where they are cleaved co-translationally by a signal peptidase generating procathepsins, the less active zymogen forms. Simultaneously, N-linked glycosylation occurs within the ER, producing high levels of mannose in the procathepsins [34]. Procathepsins later travel through the Golgi stocks where the mannose residues are modified to mannose-6-phosphate moieties (M6P). The M6P-tagged procathepsins are recognized and bound by M6P receptors in the trans-Golgi network (TGN) and are either directly sorted to the endo/lysosomes or first pass the plasma membrane from where they enter the endo/lysosomes in an indirect manner. Both direct and indirect routes rely on clathrin-coated vesicles to carry the cathepsins from the TGN or plasma membrane to the endo/lysosomes. Once the cathepsins are trafficked to endo/lysosomes, free M6P receptor is transported back to the TGN [35]. Inside lysosomes cleavage of propeptide converts procathepsins to mature active cathepsins. This activation occurs via different modes such as auto-activation or trans-activation or both. During the auto activation the pH inside the lysosomes enables the cleavage of propeptide by the catalytic site of the same enzyme, while trans-activation requires help of other proteases. For instance, cathepsin B, H, L, S, and K are activated by auto-activation, while cathepsins C and X need cathepsins L and S for their activation [36,37]. Cathepsin D is found to be processed by partial auto-activation and requires cathepsin B and L for further maturation [38]. Further, procathepsin D is known to undergo a two-step maturation process in the endo/lysosomal compartments: in the first step, propeptide is partially cleaved to generate an active single-chain intermediate which upon reaching lysosome undergoes second processing in the region of T^{155}–K^{173} to yield a double-chain mature cathepsin D [39].

M6P-Independent Sorting

While most of the lysosomal enzymes are dependent on M6P for their transport, several studies have reported the existence of M6P-independent transport routes of cathepsins to reach endo/lysosomes with the aid of alternative receptors. One such alternative receptor protein is sortilin, a trans-membrane Golgi protein, which was shown to be involved in the sorting of cathepsin H and cathepsin D in COS-7 cells [40]. In mouse embryonic fibroblasts cathepsin B and D are known to be captured by the membrane proteins LRP1 (low-density lipoprotein receptor-related protein 1) and LDLR (low-density lipoprotein receptor) [41,42]. While procathepsin D is known to complex with sphingolipid activator precursor protein prosaposin, procathepsin B is known to rely on its membrane association to enter lysosomes independent of M6P route [43–45]. Recently, type 1 transmembrane protein SEZ6L2 was linked with

sorting of cathepsin D in neurons [46]. Thus, cell-type, post-translational processing, and modifications play an important role in the sorting of cathepsins towards lysosomes.

2.3. Physiological Functions of Cathepsins in the Endo/Lysosomes

Cathepsins carry out many proteolytic events in the compartments of the endocytic pathway thus contributing to the protein turn-over and normal metabolism of the cell. The pH inside the endo/lysosomal compartment favors cathepsin activity while it induces conformational changes in the substrates leading to their cleavage by cathepsins, and thereby helping cathepsins to successfully degrade the cargo transported to the endo/lysosomes [9,47].

2.3.1. Immune Responses

Cathepsins display significant roles predominantly in the endosomes of immune cells. They are known to participate both in the innate and adaptive immune responses. During the innate immune responses, lysosomal cathepsins have been shown to cleave the ectodomains of Toll-like receptors (TLRs) 7 and 9 that are expressed on endo/lysosomal membranes, where TLRs recognize nucleic acids of phagocytosed microbes. The processed forms of TLR 7 and 9 then recruit the adaptor protein MyD88 leading to activation of TLR signaling pathways [48]. During adaptive immune responses, T lymphocytes recognize processed antigens on the surface of antigen-presenting cells (APCs) that are bound to major histocompatibility complex (MHC) molecules. While MHC class I molecules present processed antigenic peptides that are derived from the cytosol, MHC class II molecules present peptides derived from the endo/lysosomal compartment. Further, MHC class II molecules require an invariant chain (Ii), a glycoprotein necessary for their folding and assembly. Various cathepsins are found to be involved in the (I) proteolytic processing of antigens into short peptides and (II) degradation of the invariant chain thus facilitating adaptive immune responses [49,50]. However, Deussing et al. [51] demonstrated that cathepsins B and D are non-essential in MHC II mediated antigen presentation.

2.3.2. Autophagy

Cathepsins participate in autophagy, an essential catabolic process which delivers cytosolic constituents to lysosomes for their subsequent degradation in order to maintain cell homeostasis [52]. As demonstrated by Dennemarker et al. [53], cathepsin L deficient primary mouse embryonic fibroblasts showed normal initiation of the autophagy process, autophagosome formation as well as autophagosome–lysosome fusion but impaired degradation of autolysosomal content. Despite this impairment of autolysosomal turnover due to the lack of cathepsin L, the viability of the cells was not affected. This implies that autolysosomal degradation is not solely dependent on cathepsin L and is likely compensated by cathepsin D as evidenced by the increased levels of cathepsin D in cathepsin L knock out cells. In addition, cathepsins also regulate lysosome and autophagosome populations. Cathepsin B is known to degrade the calcium channel MCOLN1/TRPML1 in the lysosomes, leading to the suppression of transcription factor TFEB and thus inhibiting the expression of autophagy-related proteins. This response is known to keep in check the lysosomal biogenesis and population of cellular autophagosomes [54]. Cathepsin S is required for the fusion processes of autophagosomes and lysosomes and its deficiency results in increased number of autophagosomes. Moreover, cathepsin S-mediated autophagic flux is known to induce M2-type polarization of tumor associated macrophages, which would then contribute to tumor [55].

2.3.3. Growth and Development Related Functions

Cathepsins regulate growth and development related processes by processing various hormones and growth factors. For instance, cathepsin B degrades a variety of substrates including insulin-like growth factor-1 (IGF-I), glucagon, pituitary hormone, thyroglobulin [56,57]. Additionally, cathepsin B in the adipocytes is known to cleave perilipin 1 (PLIN1), a lipid droplet-associated protein leading to increased lipolysis in obese adipose tissue [58]. Further, the proteolytic events regulated by

cathepsins are critical in the control of biological processes including ovulation, neuronal development and fertilization. For instance, cathepsin L is one of the key proteases upregulated in granulosa cells of ovulatory follicles mediating follicular rupture during ovulation [59]. Cathepsin D is known to process vitellogenin and together with B and L, is involved in oogenesis in lower vertebrates. Cathepsins are extensively involved in embryo development. Relevantly, knock down of cathepsin D led to tissue defects including eye, skin and swim bladder in zebra fish [60] and caused intestinal mucosa damage, atrophy of myelin sheath and early death in mice [61]. Similarly, mice deficient in cathepsins B and L developed atrophy in the cerebral and cerebellar regions of the brain, suggesting their necessity for neuronal development [62].

2.4. Pathological Role of Cathepsins in the Endo/Lysosomes

Inactivation or loss-of-function of cathepsins results in inappropriate degradation and abnormal accumulation of substrates in lysosomes leading to various diseases including lysosomal storage disorders (LSD). Further, defective proteolytic events by cathepsins can lead to several LSDs, namely, galactosialidosis [63] neuronal ceroid lipofuscinosis (CLN) type 10 and 13 [63,64], Papillon–Lefèvre syndrome [65], pycnodysostosis [66], and Alzheimer's disease [21]. Further, given the important role of cathepsins in autophagy, impaired proteolysis by cathepsins can lead to massive accumulation of autophagosomes which eventually can cause pathologies including cellular senescence, inflammasome activation [67] and Saposin (Sap) C deficiency, a rare variant form of Gaucher disease [68]. Impaired activity of Cathepsin D and L would result in accumulation of α-synuclein amyloid fibrils in the brain tissue leading to synucleinopathies [69]. Alterations or loss of functions in the cathepsin activity are known to have adverse effects on reproduction and fertility [70]. Thus, consequences of cathepsin inactivation translate to a wide variety of clinical complications. Detailed functions of individual cathepsins and the associated pathologies are mentioned in the Table 1.

Table 1. Cathepsins in the endo/lysosomal compartment.

Cathepsin	Enzyme Commission Number	Catalytic Type	Function	Pathology	OMIM ID	Reference
Cathepsin A	3.4.16.5	serine	dual function: a. protective:β-galactosidase and neuraminidase b. degradative: bioactive peptides like bradykinin, angiotensin, oxytocin, endothelin 1	hypertension Galactosialidosis	256540	[63]
Cathepsin B	3.4.22.1	cysteine	degrades amyloid-β; activation of pro-hormones and pro-enzymes; trypsin activation; promotes viral entry into cells	Alzheimer's; gaucher disease acute pancreatitis		[21,68]
Cathepsin C	3.4.14.1	cysteine	inflammatory responses and activation of serine proteases including neutrophil elastase and cathepsin G	Papillon–Lefèvre syndrome Periodontitis	245000	[65]
Cathepsin D	3.4.23.5	aspartic	embryo and neuronal development brain antigen processing of α-Synuclein; tau, amyloid β, apoE; degradation of hormones, proenzymes and growth factors	Alzheimer's disease; CLN 10 Parkinson's; Huntington's	610127	[20,61,64]
Cathepsin E	3.4.23.34	aspartic	carboxypeptidase A and IgE processing	atopic dermatitis		[71]
Cathepsin F	3.4.22.41	cysteine	li chain processing and MHC-II class responses	CLN 13	615362	[63]
Cathepsin G	3.4.21.20	serine	auto antigen processing	auto-immune diseases		[72]
Cathepsin H	3.4.22.16	cysteine	prohormone processing	type 1 diabetes		[9]
Cathepsin K	3.4.22.38	cysteine	TLR signaling; processing of β-endorphin in brain	periodontitis; pycnodysostosis	265800	[73,74]
Cathepsin L	3.4.22.15	cysteine	antigen and li chain processing; prohormone processing; degradation of α-Synuclein, tau; promotes viral entry into cells	Parkinson's disease; frontotemporal dementia		[19,49]
Cathepsin S	3.4.22.27	cysteine	antigen processing and presentation; li chain processing	auto-immune diseases		[50]
Cathepsin X	3.4.18.1	cysteine	T-cell migration and invasion	-		[75]
Cathepsin O	3.4.22.42	cysteine	-	-		
Cathepsin V	3.4.22.43	cysteine	natural killer cell and CD8+ cytotoxic cell production	thymic pathology		[76]
Cathepsin W	3.4.22.-	cysteine	component of endoplasmic reticulum proteolytic machinery	-		[77]
Cathepsin Z	3.4.18.1	cysteine	intracellular protein turnover	-		[78]

- Implies that no function or pathology is yet discovered for the respective cathepsins. CLN stands for ceroid lipofuscinosis, neuronal; OMIM stands for online mendelian inheritance in man.

3. Cathepsins in Cytosol

As described in the previous section, proteolytic functions of cathepsins mainly occur in the endo/lysosomal compartments. However, most of the cathepsins are released into the extralysosomal locations such as cytosol, nucleus, and mitochondria where they perform crucial tasks. In the current section, we describe the mechanism of cathepsin translocation into different regions of the cell and their respective functions.

3.1. Mechanism of Translocation

Perhaps one of the most simplistic mechanisms though which cathepsins are translocated to cellular compartments other than lysosomes is by leaking outside of lysosomes. Lysosomes are surrounded by a limiting membrane, which is a phospholipid bilayer that is characterized by variety of integral membrane proteins, which together protect the organelle from the degradative enzymes [79]. Damage to the lysosomal membrane components or disturbances in membrane fluidity and structure can influence lysosomal stability and subsequently lead to rupture of lysosomes, a process called lysosomal membrane permeabilization (LMP). LMP is induced by a plethora of stimuli including oxidative stress, lysosomotropic agents, as well as some endogenous cell death effectors. While partial permeabilization of the lysosomal membrane induces apoptosis (programmed cell death), complete lysosomal rupture leads to necrosis (reviewed in [80]).

3.1.1. Oxidative Stress-Induced LMP

Lysosomal destabilization is recognized feature during oxidative stress-mediated cell damage. The initial burst of reactive oxygen species (ROS) may be generated by different triggers inside or outside of the lysosomes. For example, ceramide accumulation or ingestion of heavy metals such as silica or asbestos is known to increase NAPDH oxidase in the lysosomes to generate ROS. The generated free radicals interact with free intralysosomal iron forming highly reactive hydroxyl radicals in a Fenton-type reaction [80]. Such hydroxyl radicals induce LMP by causing lipid peroxidation of lysosomal membranes thereby forming lipofuscins and further damaging lysosomal membrane proteins (reviewed in [81]). An oxidative burst elicited by interferon-γ was reported to induce LMP and cathepsin release [82]. Further, ROS is known to modify lipids and lysosomal trapping of oxLDL has the potential to damage and disrupt the lysosomal membrane leading to the secretion of cathepsins [83,84]. Additionally, ROS is found to be generated outside of the lysosomes by destabilized mitochondria, inhalation of exogenous pollutants and ionizing radiation leading to LMP (reviewed in [85,86]).

3.1.2. Lysosomotropic Agents

Lysosome-targeting agents, referred to as lysosomotropic agents and lipid detergents cause LMP either by direct membrane lysis or by osmotic lysis of lysosomal membrane. Examples of agents that cause direct membrane lysis include O-methyl-serine dodecylamide hydrochloride (MSDH), N-dodecylimidazole, n-β-naphthylamide, and endogenous compounds such as lipofuscin. Due to their amphiphilic nature, these agents partition between the water phase and the phospholipid bilayer of lysosomal membrane. Further, accumulation of the lysosomotropic agents and molecules leads to thinning of the lysosomal bilayer and subsequent solubilization of lysosomal membrane (LM) (reviewed in [87]). Lysosomotropic amines, such as chloroquine or ammonium chloride and peptides such as (LeuLeu)nOMe are known to change the permeability of LMs and thus leading to increased influx of solutes into lysosomes and eventually leading to osmotic lysis [88]. Loss of membrane cholesterol or modification of membrane lipids by lipases such as sphingomyelinase and ceramidase is known to induce LMP by increasing the lysosomal permeability for potassium ions and protons and subsequent osmotic lysis [89,90]. Thus, various molecules can cause LMP, leading to leakage of cathepsins into the cytosol.

3.2. Transport of Cathepsins to Different Regions of Cytosol

Besides LMP, other mechanisms such as alternative translation or exon skipping can lead to extra lysosomal translocation of cathepsins. Translation initiation at a different start site produces cathepsins which are devoid of signal peptide, while exon skipping generates truncated cathepsins with modified signal sequences thus misrouting cathepsins from their biosynthetic pathway to locations such as cytosol, nucleus, and mitochondria. For instance, translational initiation at downstream AUG site is known to localize cathepsin L in nucleus [91] and alternative splicing in cathepsin B mRNA with missing exons at 2 and 3 is known to direct cathepsin B to mitochondria [92], Another report by Bestvater et al. [93] proposed an alternative targeting signal besides the usual N-terminal signal peptide for cathepsin B namely, a signal patch within its heavy chain domain that facilitates its nuclear import.

3.3. Physiological Functions of Cathepsins in the Cytosol

Although cathepsins do not retain optimal activity at the neutral pH of the cytosol, their proteolytic activity is known to be preserved by substrate binding and acidification of the cytosol observed under certain conditions like apoptosis and cathepsins in the cytosol are known to mediate key physiological processes as described below.

3.3.1. Apoptosis and Necroptosis

Apoptosis is a highly regulated, fundamental physiological process of cell death responsible for removal of damaged/aging cells by activation of caspase family of proteins. Apoptosis involves two different pathways; intrinsic pathway, also known as the mitochondria pathway, or the extrinsic pathway involving death ligands (reviewed in [94]). The mitochondria pathway is regulated by B-cell lymphoma-2 (Bcl-2) family proteins. Bcl-2 family consists of both anti-apoptotic members such as Bcl-2 and Bcl-xL and pro-apoptotic proteins including Bax, Bak, and Bid [95]. By genetic modification or use of pharmacological inhibitors, several studies have established that cathepsins in the cytosol play an important role in apoptosis, specifically by activating other apoptotic proteases [96]. Cytosolic cathepsins B, D, and L are implicated in the degradation of Bid, resulting in its activation and translocation to mitochondria. This translocation leads to cytochrome C release from mitochondria followed by caspase activation, and thus initiating apoptotic cell death. Simultaneously, cathepsins are involved in the degradation of anti-apoptotic proteins Bcl-2, Bcl-xL, Mcl-1, and XIAP (X-linked inhibitor of apoptosis), promoting apoptosis [97]. Additionally, in T cells, cathepsin-D-mediated apoptosis involves the activation of Bax, and the release of apoptosis-inducing factor (AIF) and cystatin c. This process has been shown to be independent of Bid cleavage and initiates apoptosis by directly activating the initiator caspase-8 [98–100].

Recent studies have shown that cathepsins regulate programmed necrosis termed necroptosis. Necroptosis is initiated by various stimuli and requires the kinase activity of receptor-interacting serine/threonine kinase1 (Rip1). In macrophages, it has been reported that cathepsins B and S are known to cleave receptor-interacting protein 1 (Rip1) kinase and thus limit macrophage necroptosis [101].

3.3.2. Inflammation

Cytosolic cathepsins are shown to be involved in mediating inflammatory responses via activation of inflammasomes. The NLRP3 inflammasome is a multi-protein complex which is activated upon bacterial infections, LMP or cellular damage. Upon activation, pro-caspase1 is converted to active caspase1 by autocatalysis. Active caspase1 then proceeds to cleave the cytokine precursors pro IL-1β and IL-18 into their mature secreted forms (reviewed in [102]). Gene knockout and siRNA knockdown of cathepsins B, C, S, L, and Z resulted in a suppression of IL-1β secretion [103–105]. However, cathepsins are not shown to directly cleave either caspase-1 or IL-1β suggesting that they operate upstream of inflammasome activation [103]. Additionally, Cathepsins Z and S are known to

compensate for the activity of cathepsins B, C, and L in LMP-mediated inflammasome activation by unknown mechanisms [106].

3.3.3. Functions of Nuclear Cathepsins

Cathepsins in the nucleus are known to process transcription factors that control cell cycle progression thus facilitating cell proliferation and differentiation (reviewed in [107]. The CDP/Cux/Cut transcription factors are a group of highly conserved proteins in higher eukaryotes that are involved in cell cycle proliferation, particularly in the transition from G1 to S phase. Cathepsin L in the nucleus is known to cleave the CDP/Cux, which accelerates progression into S phase of the cell cycle [108]. Nuclear cathepsin D promotes cell proliferation by acting as co-factor for Tricho-rhino-phalangeal syndrome Type 1 (TRPS1) transcription factor and is known to enhance mammary gland differentiation by cleaving histone H3 [109]. Nuclear cathepsins are known to regulate transforming growth factor-β (TGF-β) signaling, an important pathway normal growth and tissue development whose mis regulation can lead to carcinogenesis. The downstream effectors of TGF-β signaling, the Smad proteins, are phosphorylated and activated by receptors such as importinβ which mediate pSmad nuclear translocation, where they regulate transcription. Cathepsins B, K, L, and S are known to localize to nuclear membrane where they exert differential effects in the translocation of pSMAD2 and pSMAD3 proteins by modulating importin β expression and thus regulate TGF-β signaling [110]. Physiological functions of cytosolic cathepsins are listed in Table 2.

Table 2. Function of cathepsins in the cytosol.

Cathepsin	Extra Lysosomal Location	Function	Reference
Cathepsin B, D and L	cytosol	proteolytic processing of Bid during apoptosis	[97,111]
Cathepsin B, C, L, S and Z	cytosol	NLRP3 inflammasome activation	[103–106]
Cathepsin B	cytosol	regulation of hepatic lipid metabolism by degrading liver fatty acid binding protein	[112]
Cathepsin L and H	nucleus	cell cycle regulation	[91]
Cathepsin B, K, L and S	nucleus	TGF-β signaling	[110]
Cathepsin B	nucleus	bile-salt induced apoptosis	[113]
Cathepsin A, E, G, S, X, O, V, W, Z *	-	-	-

* Roles for these remaining cathepsins outside of the lysosome have not yet been reported.

3.4. Pathological Functions of Cathepsins in the Cytosol

Lysosomal disruption and the subsequent release of cathepsins in the cytosol can have detrimental effects. For instance, though apoptosis is a highly regulated fundamental physiological process, there are many pathological conditions including neurodegeneration and ischemia that involve excessive apoptosis in which cytosolic cathepsins are known to play an active role [96,114]. Accordingly, substantial evidence supports the contribution of cathepsins from ruptured lysosomes in the pathology of many neurodegenerative diseases [115]. In contrast to healthy brain, in Alzheimer's brain, cathepsin D is found in the cytosol and such cytosolic cathepsin D is known to cleave tau protein generating truncated form of tau which in turn forms paired helical filaments leading to neurofibrillary degradation [115]. Cytosolic cathepsin D is also implicated in glaucoma by promoting apoptosis in trabecular mesh work cells, which maintain intraocular pressure of the eye [116]. Furthermore, cytosolic cathepsin D has been proposed as a biomarker of age-related neurodegenerative disorders [117]. In line, it has been found that cathepsin D translocation into the cytosol led to pronounced age-related changes in rats, by increasing the degeneration of neurons [117,118]. NLRP3 inflammasome is essential for defending against bacterial infections and mis regulated NLRP3 inflammasome has been implicated in metabolic inflammatory disorders including type 2 diabetes, atherosclerosis, heart reperfusion injuries, and chronic kidney diseases (reviewed in [119]). Given the known role of cathepsins in modulating

inflammasome activation it then also indirectly suggests a pathological relevance of cathepsins in these disorders.

Another cytosolic cathepsin that is associated with disease conditions is cathepsin L. In pathological conditions such as proteinuria and glomerular kidney disease, translocation of cathepsin L to cytosol has been documented [120]. Here, in contrast to its lysosomal counterpart, cytosolic cathepsin L in podocytes (cells in the Bowman's capsule of the kidneys), is known to degrade cytoskeleton proteins, namely, CD2-associated protein, synaptopodin and dynamin, thus leading to the reorganization of the actin cytoskeleton, proteinuria and subsequent renal failure [121]. Nuclear cathepsin L activity is associated with polycystic kidney disease [121] and alterations in its activity significantly influenced colorectal cancer disease progression [108]. Nuclear cathepsin F activity is found to be correlated with markers of transcriptional regulation in hepatic stellate cells [122]. Mitochondrial procathepsin B is known to induce morphological changes in mitochondrial integrity and thus can lead to cell death [123]. Taken together, cathepsins perform dynamic functions outside of the lysosomes based on their cytosolic location.

4. Cathepsins in the Extracellular Space

Numerous lines of evidence demonstrated the presence of cathepsins in the extracellular space. Although the extracellular localization of cathepsins is more commonly observed during pathological conditions, cathepsins are mostly involved in the bone remodeling and plasma membrane repair during physiological conditions.

4.1. Mechanism of Translocation

Cathepsins are normally secreted via lysosomal exocytosis or by alternative sorting from Golgi. Usually secretion of cathepsins is often accompanied by their over expression which is commonly observed in cancer and inflammatory conditions [16]. Immune cells are known to secrete high levels of cathepsins. Additionally, osteoclasts, keratinocytes, thyroid cells, and smooth muscle cells also release cathepsins into the extracellular space [124].

4.1.1. Lysosomal Exocytosis of Cathepsins

The secretory pathway of lysosomes, known as lysosomal exocytosis, has been reported in many types of cells and is induced by various stimuli such as wound, cellular stress, cancer, or by signals from cytokines [125]. The induction of exocytosis occurs by the recruitment of lysosomes to the periphery of the cells. This movement of lysosomes is mediated along microtubule track with the help of various kinesins and a multi subunit complex named BLOC-one-related complex (BORC) that promotes kinesin-mediated lysosome movement toward the cell periphery [126]. The movement of lysosomes to the periphery is followed by docking, where the lysosome and plasma membrane are brought into closer contact with the help of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes, namely the interaction of v-SNARE (vamp7) on lysosomal membrane with t-SNARE (synaxin 4 and SNAP-23) on the cytoplasmic side of the plasma membrane (PM) [127]. Both lysosomes and PM contain negatively charged lipids in their outer and inner layers, respectively. Hence, cells rely on calcium ions (Ca^{2+}) to bridge the opposing charges on the membranes. Further, lysosomal docking and fusion are regulated by transcription factor EB (TFEB). EB modulates lysosomal exocytosis by triggering intracellular Ca^{2+} elevation through the endo/lysosomal cation-channel mucolipin 1 (MCOLN1) [128]. Finally, the fusion of lysosomes with the PM results in the secretion of lysosomal components into the extracellular space. Castro-Gomes et al. [129] elegantly demonstrated that cathepsin B and L are released extracellularly by lysosomal exocytosis and participate in PM repair using in vitro systems.

4.1.2. Alternative Sorting of Cathepsins into Extracellular Space

As described in the Section 2.1 of this review, cathepsins are trafficked to endo/lysosomal compartments of the cell with the help of M6P receptors. Changes in the pH are known to disrupt the recycling of M6P to the Golgi, where its absence leads to the potential re-routing of procathepsins into the extracellular space directly or packaged into the secretory vesicles [37,130]. In contrast, during conditions such as bone resorption, secretion of active form of cathepsins is observed suggesting that the secretion is context dependent. Once secreted, cathepsins can be found attached to the caveolae on the PM, as seen in case of cathepsin B [131] or released in the extracellular space directly or packed inside the secretory vesicles.

4.2. Physiological Function of Extracellular Cathepsins

Cathepsins require acidic pH for their optimum activity in contrast to the neutral pH found in extracellular space. However, cathepsins are often secreted as less active procathepsins which are normally stable at neutral pH [132]. For cathepsins secreted in the mature active form, vacuolar H+- ATPases (V-ATPase) are known to provide a local acidic hub in the pericellular to facilitate their prolonged activity in the extracellular space [133]. For instance, in bone lacunae, V-ATPase and the chloride channel create a low pH extracellular environment with the help of H+ and Cl- ion flow [134]. Cathepsins in the extracellular matrix are known to degrade many components of the ECM and thus participate in physiological processes including wound healing [135], bone remodeling [136,137] and processing of prohormones [8].

4.2.1. ECM Degradation

ECM is composed of fibrous proteins such as elastin, collagen, proteoglycans, and fibronectins that form the intricate meshwork for holding the cells embedded within the tissues Further, ECM undergoes constant remodeling and ECM components have several binding sites for growth factors that ultimately control cell adhesion, proliferation, migration, and polarity [138]. ECM conducts mechanical signals that further activate cytoskeletal and intracellular signaling pathways. In healthy tissue, ECM homeostasis is mainly regulated by cathepsins and matrix metalloproteases (reviewed in [139]).

Bone remodeling is a continuous process that involves bone resorption and remodeling performed by specialized cells called osteoclasts. Further, bone and cartilage predominantly contain type 1 collagen. During bone resorption, osteoclasts attach to the surface of bone leading to the creation of an extracellular compartment which is isolated from general extracellular fluid (reviewed in [140]). Numerous studies showed that the active cathepsin K released from osteoclasts into the resorption lacunae is known to degrade type 1 collagen and elastin and thus plays a pivotal role in bone resorption [17,137,139,141]. Moreover, cathepsins are known to degrade two bone ECM proteins, osteocalcin, and osteonectin. While osteocalcin is involved in bone formation and insulin metabolism, osteonectin helps in cell matrix interactions [139,142]. Further, proteoglycans are major constituents of ECM are composed of core protein with covalently attached glycosaminoglycan molecules (GAGs). Various cathepsins are known to cleave the protein core of proteoglycan. For example, cathepsins B and L cleave perlecan, a heparan sulfate proteoglycan, generating LG3 peptide, which is known to have neuroprotective role in brain ischemia [143,144].

4.2.2. Functions of Cathepsins on the Plasma Membrane

Cathepsins on the cell surface are known to be involved in plasma membrane repair. Cathepsin B released from keratinocytes attaches to cells surface where it is known to be involved in keratinocyte migration by degrading components of ECM during wound healing [145]. Another cathepsin that translocate to the plasma membrane is cathepsin X which helps with processes of cell adhesion and signaling [75]. β integrins are cell surface proteins that help in cell adhesion and invasion. Cathepsin X on the plasma membrane is known to cleave regulatory motifs in two different types of

β2 integrin receptors. By activating β2 integrin receptor Mac-1, cathepsin X enhances the adhesion of immature dendritic cells to ECM, leading to their activation. Additionally, cathepsin X activates another β2 integrin receptor, LFA-1 enhancing the proliferation of T lymphocytes thus accelerating immune responses [75,146].

4.2.3. Functions of Cathepsins in the Secretory Vesicles

Neurons and endocrine cells carry out cell–cell communication with the help of peptide neurotransmitters. Secretory vesicles in these cells provide regulated secretion of neurotransmitters, which are first synthesized as inactive prohormones. Proteolytic processing of the proproteins or prohormones occurs in the secretory vesicles by cathepsins [147]. Numerous studies have identified cathepsin L and V as key processing enzymes for production of numerous peptide neurotransmitters including neuropeptide Y, enkephalin, cholecystokinin, and dynorphins [25,148]. The environment inside the vesicles is known to have acidic pH which promotes the function of cathepsins to generate active peptides [149,150].

4.3. Pathological Functions of Extracellular Cathepsins

While ECM remodeling is an important physiological process, aberrant ECM dynamics can lead to uncontrolled cell proliferation, invasion, and differentiation leading to fatal pathologies including atherosclerosis, cancer, and tissue fibrosis [138]. Extracellular cathepsin activity have been implicated in many of these diseases as elaborated below.

4.3.1. Cancer

Cancer results from abnormal cell proliferation in the body. Increased or abnormal proteolytic activity of cathepsins is known to degrade ECM components facilitating migration and invasion of tumors leading to malignancy (reviewed in [124]). Cathepsins can be secreted from cancer cells and infiltrating immune cells called tumor-associated macrophages (TAMs). Over secretion of cathepsins is associated with their abnormal expression. Several molecular factors that regulate expression of cathepsins in tumor microenvironment are defined. Signal transducer and activator of transcription 3 and 6 (STAT3, STAT6) are known to promote the secretion of procathepsins B, C, S, and Z mainly from macrophages [151]. Collagen 1 is known to induce secretion of procathepsin B by regulating Ets1 transcription factor [152]. Additionally, it has been postulated that cancer microenvironment downregulates M6P receptor mRNA due to overexpression of cathepsins. Due to its weak affinity towards M6P receptor, cathepsin L is known to be directly secreted from TGN before binding to M6P receptor in fibrosarcoma cells [153]. Metastatic tumor cells are known to have defective lysosomal sorting of procathpesin D resulting in its secretion. Further, the acidic tumor microenvironment not only favors the maturation of procathepsins but also promotes their activity [154].

Elevated levels of extracellular cathepsins have been identified in various cancers such as breast, lung, colon, pancreas, skin, prostate, bladder, ovary, and head and neck [25]. In addition to increased levels, increased activity of cathepsins is often associated with activation of tumor-associated cytokines, shedding and cleaving cell–cell adhesion molecules, thereby destroying cell contact and contributing to metastasis. For example, E-cadherin is an important cell adhesion molecule and epithelial tumor suppressor. Extracellular cathepsins B, L and S are known to cleave E-cadherin promoting tumor invasion into surrounding tissues [155]. In contrast, secreted cathepsin D is known to cleave 23 kDa prolactin, a lactogenic hormone produced by pituitary gland to a 16 kDa fragment which has antiangiogenic properties in rat mammary epithelial cells [156] and in bovine corpus luteum but not in humans [157]. Another mechanism through which extracellular cathepsins contribute to cancer progression is by shedding, a process by which proteases release the extracellular domains of cell surface proteins from the cells [158]. Shedding converts membrane-associated proteins into soluble ones and thus reduces their cell surface expression that in turn is a means of regulation for subsequent physiological processes. Apart from several cell adhesion molecules (CAMs) identified as substrates

for shedding, cathepsins also target the Ras signaling pathway, a major intracellular signaling pathway in cancer progression. Extracellular cathepsins S and L are known to shed plexins and epidermal growth factor receptor (EGFR), both of which are substrates for Ras pathway activation [16,158]. Similarly, extracellular cathepsin D is known to degrade the ECM proteins thus freeing the embedded growth factors such as fibroblast growth factor. Growth factors are complex polypeptides that have critical roles in basement membrane disruption, cell migration, and tumor metastasis in auto and paracrine manner [154].

4.3.2. Metabolic Disorders

Lipoprotein accumulation and metabolism are important contributors to various diseases including cardiovascular diseases and obesity -associated disorders such as non-alcoholic steatohepatitis (NASH). Extracellular cathepsins are found to be involved in transport, efflux, and processing of lipoprotein molecules or their receptors (reviewed in [159]). For instance, extracellular cathepsins F, K, and S are known to degrade cholesterol acceptors on the cell surface, thereby reducing cholesterol efflux and initiating foam cell formation, a key feature of atherosclerosis [24]. Increased presence of low-density lipoprotein (LDL) is a characteristic of both atherosclerosis and NASH. Extracellular cathepsin D is known to proteolytically modify apolipoprotein B-100 (apoB), component of LDL and subsequently leading to LDL accumulation in arterial intima [160,161]. In agreement, extracellular cathepsin D inhibition is known to reduce hepatic steatosis [162]. Further, LDL accumulation in the arterial intima can lead to its oxidation which enhances inflammatory responses, that in a positive feedback loop promotes further secretion of cathepsins leading to exacerbation of lipid accumulation and inflammation (reviewed in [163]). Similar to extracellular cathepsin D, extracellular cathepsin S is known to promote inflammation by cleaving chemokines such as fractalkine (CX3CL1) that help in leukocyte migration and neuropathic pain [164]. Finally, extracellular cathepsin activity is involved in lung fibrosis, osteoarthritis, osteoporosis and rheumatoid arthritis which are summarized in Table 3.

Table 3. Cathepsins in the extracellular space.

Cathepsin	Substrate	Pathological State	Reference
Cathepsin B, K, and L	proteoglycan	osteoarthritis	[137,165]
Cathepsin B, L, G, and S	fibronectin	cancer and adipogenesis	[166–169]
Cathepsin B, L, and S	laminin	cancer neovascularization, intestinal trauma	[166–168]
Cathepsin K	collagen type I	osteoporosis, rheumatized arthritis, osteoarthritis	[137]
Cathepsin B, K, L, and S	collagen type 2	lung fibrosis, cardiovascular diseases and cancer	[138,139]
Cathepsin B	tenascin	cancer	[170]
Cathepsin B, K, L, and S	aggrecan	osteoarthritis	[136,171]
Cathepsin L, S, and B	plexin	tumorigenesis	[158]
Cathepsin S	fractalkine	neuropathic pain	[164]
Cathepsin D	fibroblast growth factor	breast cancer	[172]
Cathepsin V	elastin	cancer	[173]
Cathepsin X	CXCL-12	-	[174]
Cathepsin W	-	cell-mediated cytotoxicity	[175]
Cathepsin A, C, E, F, O, and Z *	-	-	

* Role of these extracellular cathepsins in pathologies in not known.

The mechanisms involved in the translocation of cathepsins and their respective site-specific functions are illustrated in Figure 1.

Figure 1. Site-specific functions of cathepsins. (**A**) cathepsins in the lysosomes (represented by orange arrows): Cathepsins are synthesized as preprocathepsins in the endoplasmic reticulum and transported to endo/lysosomes via Trans-Golgi network where the acidic pH enables their maturation. Cathepsins in the lysosomes are mostly involved in protein degradation besides participating in autophagy. (**B**) cathepsins in the cytosol (represented by purple arrows): Lysosomotropic agents, ROS or accumulation of modified lipids (oxLDL) leads to lysosomal membrane permeabilization (LMP), releasing cathepsins into the cytosol. Cytosolic cathepsins participate in various activities. For example, cathepsins trigger the inflammasome and promote apoptosis and necroptosis by cleaving various proteins. (**C**) Cathepsins in the extracellular space (represented by blue arrows): Lysosomal exocytosis involves the secretion of lysosomal contents into the extracellular space with the help of several protein-receptor interactions and Ca^{+2} ion gradient. Cathepsins are released in the form of procathepsins or enclosed in the secretory vesicles or as active cathepsins. Secreted cathepsins remain attached to the plasma membrane or are released into the extracellular space. Cathepsins on the plasma membrane cleave proteins like integrins. Secreted cathepsins mainly participate in extracellular matrix degradation and thus help in wound healing. However, excessive ECM cleavage facilitates tumor invasion and promotes cancer. While in the extracellular space cathepsins also shed the ectodomains of transmembrane receptors, leading to either activation or inhibition of cell signaling. ROS: reactive oxygen species; LMP: lysosomal membrane permeabilization; NPC1: Niemann–Pick disease type C1; CD36: cluster of differentiation 36; Figure is created with permission from Servier Medical Art image bank.

5. Targeting Cathepsins in Disease Management

Localization of cathepsins (endo/lysosomal/cytosolic/extracellular space) governs several aspects of cathepsin function. A wealth of knowledge has been published on the differential expression and functional profiles of cathepsins in various pathologies making them potential diagnostic biomarkers and most desirable therapeutic targets.

Cathepsin levels and activity have been found to be upregulated in sera and tumors of many cancer patients [176,177]. For instance, expression and activity levels of cathepsins B and L corelated with breast cancer progression [178]. Furthermore, B and L cathepsins also correlated with relapse rate after treatment in primary breast cancers [178]. In cancers concerning colon, lung, brain and head and neck, concentration of cathepsins B and L within tumors correlated with survival probability [179]. Moreover, cathepsin L levels were increased in sera of patients with pancreatic [180] and liver cancers [181]. Serum cathepsin H levels were found to be increased in patients with lung [182], melanoma [183], and colorectal cancers [184]. The findings of these recent studies have alluded to a potential of utilizing cathepsins as biomarkers of cancer though few studies show some discrepancies in the outcomes of cathepsin expression and activity during cancer (reviewed in [185]). In addition to cancer, plasma levels of cathepsin S, K, and L have been proposed as biomarkers in coronary artery disease, aneurysm, adiposity, and peripheral arterial disease [186]. Similarly, plasma cathepsin D levels associated with metabolic alterations in liver during NAFLD [187]. Recent studies suggested that plasma cathepsin D levels correlated with type 2 diabetic patients [188] and moreover plasma cathepsin D activity is suggested as biomarker for hepatic insulin sensitivity [189]. Cathepsins Z and K are proposed diagnostic markers for osteoporosis [190,191]. Another promising development is the use of cathepsins as fluorescent probes in diagnostic non-invasive imaging which has had success in preclinical mouse models [192].

In diseases caused by inactivation or loss-of-function of cathepsins, supplying functional cathepsins could be a valuable means to restore cellular function and ameliorate the disease. For instance, enzyme replacement therapy (ERT) replacing defective lysosomal cathepsin D by recombinant procathepsin D has been proven beneficial for CLN10 [193]. However, due to known associations of excessive extracellular cathepsin D with other pathological conditions highlighted previously in this review caution must be exercised when utilizing this therapeutic approach to avoid overaccumulation of cathepsin D in extra lysosomal locations which could possibly lead to activation of extracellular cathepsin D mediated pathological processes. When implementing the ERT approach for cathepsins, the recombinant cathepsins' mannose-6-phosphate content must be maximized to ensure their optimal uptake by tissues and to avoid their extra lysosomal accumulation. In addition, conjugating recombinant cathepsins with chaperones might help to diffuse them across cell membranes and reach target tissues including central nervous system (CNS) [194]. Additionally, close monitoring of injected levels of recombinant enzyme in patients might help in preventing any negative effects.

Increased understanding of the structure, differential expression and localization of cathepsins in various pathologies has opened a new avenue for the design of small molecule inhibitors of cathepsins with the hope of producing highly specific, targeted drugs for many diseases. Several small molecule inhibitors of cathepsin S and K are being tested in clinical trials [192]. Additionally, combinatorial therapies involving cathepsin inhibition are gaining more attention. For example, cathepsin inhibitors conjugated with radio/chemotherapy would be a potential anti-cancer treatment [195]. Further, cathepsin K clinical inhibitors for treatment of osteoporosis might have potential to attenuate cancer [196]. Unfortunately, one of the bone-specific cathepsin K inhibitors to complete phase III clinical trials, odanacatib (Merck) had to be discontinued due to risk of stroke [197]. The failure was likely due to the fact that the active-site inhibitor of K also blocked the other essential protease functions of cathepsin K [17]. One of the strategies to alleviate this problem was to identify inhibitors specific to the exosites or allosteric sites, that essentially inhibit the pathological collagenolytic activity only and thus limiting the cytotoxicity [198]. One of such exosite inhibitors of cathepsin K was successfully demonstrated in a mouse model of osteoporosis [199]. However, since not all cathepsin activities are modulated by exosite interactions it presents a limitation for the use of exosite inhibitors in certain cathepsin related pathologies. Other novel ways such as site-specific inhibition of cathepsins would also reduce their off-target limits. For instance, small-molecule inhibitors targeting only the secreted extracellular fraction of cathepsin D and not the lysosomal fraction had beneficial results in a rodent model of NAFLD [162]. Moreover, antibodies against extracellular fraction of cathepsin S efficiently inhibited

tumor growth and neovascularization in xenograft tumors [200] and improved chemotherapy efficacy in colorectal carcinomas [201]. There are still a few inhibitors targeting either extracellular cathepsins or their substrates that require further validation in clinical setting [192] as described in the Table 4. Taken together, while evidence that shows a direct link between extracellular cathepsins and various pathologies are few, current studies to date show promising therapeutic result of targeting specifically the extracellular fraction of cathepsins in their respective pathologies. Therefore, further research looking into the specific role of extracellular cathepsins and the therapeutic value of targeting them is recommended.

Table 4. List of available extracellular cathepsin inhibitors.

Inhibitor	Target	Reference
Fsn0503	antibody against extracellular cathepsin S	[200]
Nitroxoline	extracellular cathepsin B	[202]
LNC-NS-629	extracellular cathepsin B	[203]
CTD-002	extracellular cathepsin D	[162]

6. Conclusions

In conclusion, cathepsins are a group of enzymes with distinct functions at different locations inside and outside of the cells. While many recent findings helped us to further understand these roles and establish the potential for targeting, many mechanical aspects of cathepsin action are still to be explored. Currently, the extracellular role of cathepsins have gained enormous attention in the biomedical field, establishing them as non-invasive diagnostic markers and pharmacological targets in immune disorders, cancer, osteoarthritis, and metabolic diseases. Many selective cathepsin inhibitors with limited side effects are being developed and have shown success in the preclinical animal models and are awaiting validation in the clinical setting. With the advent of new mass spectrometry technologies and systems biology approaches, the future research should focus to better understand the specific substrates of cathepsins in the physiological and pathological environment. Finally, the future of cathepsins in targeted drug delivery looks more promising than ever.

Abbreviations

AIF	Apoptosis-inducing factor
ATP	Adenosine triphosphate
Bcl-2	B-cell lymphoma-2
BORC	BLOC-one-related complex
CLN	Ceroid lipofuscinosis, neuronal
CNS	Central nervous system
CX3CL1	C-X3-C Motif chemokine ligand 1
ECM	Extracellular matrix

EGFR	Epidermal growth factor receptor
ER	Endoplasmic reticulum
IGF-I	Insulin-like growth factor-1
IRES	Internal ribosomal entry site
LDL	Low-density lipoprotein
LDLR	Low-density lipoprotein receptor
LFA-1	Lymphocyte function associated antigen-1
LM	Lysosomal membrane
LMP	Lysosomal membrane permeabilization
LRP1	Lipoprotein receptor-related protein 1
LSD	Lysosomal storage disorders
MCOLN1	Mucolipin 1
MHC	Major histocompatibility complex
MSDH	O-methyl-serine dodecylamide hydrochloride
NASH	Non-alcoholic steatohepatitis
NAFLD	Non-alcoholic fatty liver disease
NCL	Neuronal ceroid lipofuscinosis
NF-Y	Nuclear factor
NPC	Niemann–Pick disease type C
OMIM	Online mendelian inheritance in man
oxLDL	oxidized low-density lipoprotein
PM	Plasma membrane
ROS	Reactive oxygen species
TAM	Tumor-associated macrophages
TFEB	Transcription factor EB
TGF	Transforming growth factor
TGN	Trans-Golgi network
TLR	Toll-like receptor
V-ATPase	vacuolar H+ ATPase
XIAP	X-linked inhibitor of apoptosis

References

1. Perera, R.M.; Zoncu, R. The Lysosome as a Regulatory Hub. *Annu. Rev. Cell Dev. Biol.* **2016**, *32*, 223–253. [CrossRef] [PubMed]

2. De Duve, C. The lysosome turns fifty. *Nat. Cell Biol.* **2005**, *7*, 847–849. [CrossRef] [PubMed]

3. Xu, H.; Ren, D. Lysosomal physiology. *Annu. Rev. Physiol.* **2015**, *77*, 57–80. [CrossRef]

4. Lawrence, R.E.; Zoncu, R. The lysosome as a cellular centre for signalling, metabolism and quality control. *Nat. Cell Biol.* **2019**, *21*, 133–142. [CrossRef]

5. Lim, C.Y.; Zoncu, R. The lysosome as a command-and-control center for cellular metabolism. *J. Cell Biol.* **2016**, *214*, 653–664. [CrossRef] [PubMed]

6. Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: From structure, function and regulation to new frontiers. *Biochim. Biophys. Acta* **2012**, *1824*, 68–88. [CrossRef]

7. Vasiljeva, O.; Reinheckel, T.; Peters, C.; Turk, D.; Turk, V.; Turk, B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. *Curr. Pharm. Des.* **2007**, *13*, 387–403. [CrossRef]

8. Brix, K.; Dunkhorst, A.; Mayer, K.; Jordans, S. Cysteine cathepsins: Cellular roadmap to different functions. *Biochimie* **2008**, *90*, 194–207. [CrossRef]

9. Patel, S.; Homaei, A.; El-Seedi, H.R.; Akhtar, N. Cathepsins: Proteases that are vital for survival but can also be fatal. *Biomed. Pharm.* **2018**, *105*, 526–532. [CrossRef]

10. Rossi, A.; Deveraux, Q.; Turk, B.; Sali, A. Comprehensive search for cysteine cathepsins in the human genome. *Biol. Chem.* **2004**, *385*, 363–372. [CrossRef]

11. Sanman, L.E.; van der Linden, W.A.; Verdoes, M.; Bogyo, M. Bifunctional Probes of Cathepsin Protease Activity and pH Reveal Alterations in Endolysosomal pH during Bacterial Infection. *Cell Chem. Biol.* **2016**, *23*, 793–804. [CrossRef]

12.   Bromme, D.; Bonneau, P.R.; Lachance, P.; Wiederanders, B.; Kirschke, H.; Peters, C.; Thomas, D.Y.; Storer, A.C.; Vernet, T. Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. *J. Biol. Chem.* **1993**, *268*, 4832–4838. [PubMed]

13.   Kirschke, H.; Schmidt, I.; Wiederanders, B.; Cathepsin, S. The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15). *Biochem. J.* **1986**, *240*, 455–459. [CrossRef]

14.   Sapolsky, A.I.; Howell, D.S.; Woessner, J.F., Jr. Neutral proteases and cathepsin D in human articular cartilage. *J. Clin. Investig.* **1974**, *53*, 1044–1053. [CrossRef] [PubMed]

15.   Naseem, R.H.; Hedegard, W.; Henry, T.D.; Lessard, J.; Sutter, K.; Katz, S.A. Plasma cathepsin D isoforms and their active metabolites increase after myocardial infarction and contribute to plasma renin activity. *Basic Res. Cardiol.* **2005**, *100*, 139–146. [CrossRef] [PubMed]

16.   Vidak, E.; Javorsek, U.; Vizovisek, M.; Turk, B. Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment. *Cells* **2019**, *8*, 264. [CrossRef] [PubMed]

17.   Vizovisek, M.; Fonovic, M.; Turk, B. Cysteine cathepsins in extracellular matrix remodeling: Extracellular matrix degradation and beyond. *Matrix Biol.* **2019**, *75–76*, 141–159. [CrossRef]

18.   Reiser, J.; Adair, B.; Reinheckel, T. Specialized roles for cysteine cathepsins in health and disease. *J. Clin. Investig.* **2010**, *120*, 3421–3431. [CrossRef]

19.   Stoka, V.; Turk, V.; Turk, B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. *Ageing Res. Rev.* **2016**, *32*, 22–37. [CrossRef]

20.   Vidoni, C.; Follo, C.; Savino, M.; Melone, M.A.; Isidoro, C. The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders. *Med. Res. Rev.* **2016**, *36*, 845–870. [CrossRef]

21.   Cermak, S.; Kosicek, M.; Mladenovic-Djordjevic, A.; Smiljanic, K.; Kanazir, S.; Hecimovic, S. Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-Like Cholesterol Sequestration and Accumulation of the Key Alzheimer's Proteins. *PLoS ONE* **2016**, *11*, e0167428. [CrossRef]

22.   Pislar, A.; Kos, J. Cysteine Cathepsins in Neurological Disorders. *Mol. Neurobiol.* **2014**, *49*, 1017–1030. [CrossRef]

23.   Nagai, A.; Murakawa, Y.; Terashima, M.; Shimode, K.; Umegae, N.; Takeuchi, H.; Kobayashi, S. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. *Neurology* **2000**, *55*, 1828–1832. [CrossRef] [PubMed]

24.   Lutgens, S.P.M.; Cleutjens, K.B.J.M.; Daemen, M.J.A.P.; Heeneman, S. Cathepsin cysteine proteases in cardiovascular disease. *FASEB J.* **2007**, *21*, 3029–3041. [CrossRef] [PubMed]

25.   Mohamed, M.M.; Sloane, B.F. Cysteine cathepsins: Multifunctional enzymes in cancer. *Nat. Rev. Cancer* **2006**, *6*, 764–775. [CrossRef] [PubMed]

26.   Naour, N.; Rouault, C.; Fellahi, S.; Lavoie, M.E.; Poitou, C.; Keophiphath, M.; Eberle, D.; Shoelson, S.; Rizkalla, S.; Bastard, J.P.; et al. Cathepsins in Human Obesity: Changes in Energy Balance Predominantly Affect Cathepsin S in Adipose Tissue and in Circulation. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 1861–1868. [CrossRef] [PubMed]

27.   Turk, B.; Turk, D.; Turk, V. Lysosomal cysteine proteases: More than scavengers. *Biochim. Biophys. Acta* **2000**, *1477*, 98–111. [CrossRef]

28.   Jean, D.; Guillaume, N.; Frade, R. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. *Biochem. J.* **2002**, *361*, 173–184. [CrossRef]

29.   Yan, S.; Berquin, I.M.; Troen, B.R.; Sloane, B.F. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. *DNA Cell Biol.* **2000**, *19*, 79–91. [CrossRef]

30.   Nakken, B.; Varga, T.; Szatmari, I.; Szeles, L.; Gyongyosi, A.; Illarionov, P.A.; Dezso, B.; Gogolak, P.; Rajnavolgyi, E.; Nagy, L. Peroxisome Proliferator-Activated Receptor gamma-Regulated Cathepsin D Is Required for Lipid Antigen Presentation by Dendritic Cells. *J. Immunol.* **2011**, *187*, 240–247. [CrossRef]

31.   Cavailles, V.; Augereau, P.; Rochefort, H. Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 203–207. [CrossRef]

32.   Berquin, I.M.; Sloane, B.F. Cathepsin B expression in human tumors. *Adv. Exp. Med. Biol.* **1996**, *389*, 281–294. [CrossRef]

33.   Mittal, S.; Mir, R.A.; Chauhan, S.S. Post-transcriptional regulation of human cathepsin L expression. *Biol. Chem.* **2011**, *392*, 405–413. [CrossRef] [PubMed]

34.   Braulke, T.; Bonifacino, J.S. Sorting of lysosomal proteins. *BBA-Mol. Cell Res.* **2009**, *1793*, 605–614. [CrossRef]

35. Coutinho, M.F.; Prata, M.J.; Alves, S. Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction. *Mol. Genet. Metab.* **2012**, *105*, 542–550. [CrossRef]

36. Verma, S.; Dixit, R.; Pandey, K.C. Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets. *Front. Pharm.* **2016**, *7*, 107. [CrossRef] [PubMed]

37. Roberts, R. Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins. *Drug News Perspect.* **2005**, *10*, 605–614. [CrossRef]

38. Laurent-Matha, V.; Derocq, D.; Prebois, C.; Katunuma, N.; Liaudet-Coopman, E. Processing of human cathepsin D is independent of its catalytic function and auto-activation: Involvement of cathepsins L and B. *J. Biochem.* **2006**, *139*, 363–371. [CrossRef] [PubMed]

39. Follo, C.; Castino, R.; Nicotra, G.; Trincheri, N.F.; Isidoro, C. Folding, activity and targeting of mutated human cathepsin D that cannot be processed into the double-chain form. *Int. J. Biochem. Cell Biol.* **2007**, *39*, 638–649. [CrossRef]

40. Canuel, M.; Korkidakis, A.; Konnyu, K.; Morales, C.R. Sortilin mediates the lysosomal targeting of cathepsins D and H. *Biochem. Biophys. Res. Commun.* **2008**, *373*, 292–297. [CrossRef] [PubMed]

41. Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Smith, G.K.; Liaudet-Coopman, E. Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis. *Oncogene* **2012**, *31*, 3202–3212. [CrossRef] [PubMed]

42. Markmann, S.; Thelen, M.; Cornils, K.; Schweizer, M.; Brocke-Ahmadinejad, N.; Willnow, T.; Heeren, J.; Gieselmann, V.; Braulke, T.; Kollmann, K. Lrp1/LDL Receptor Play Critical Roles in Mannose 6-Phosphate-Independent Lysosomal Enzyme Targeting. *Traffic* **2015**, *16*, 743–759. [CrossRef]

43. Castino, R.; Isidoro, C. The transport of soluble lysosomal hydrolases from the Golgi complex to lysosomes. In *The Golgi Apparatus*; Springer: Vienna, Austria, 2008; pp. 402–413. [CrossRef]

44. Gopalakrishnan, M.M.; Grosch, H.W.; Locatelli-Hoops, S.; Werth, N.; Smolenova, E.; Nettersheim, M.; Sandhoff, K.; Hasilik, A. Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. *Biochem. J.* **2004**, *383*, 507–515. [CrossRef]

45. Tanaka, Y.; Tanaka, R.; Kawabata, T.; Noguchi, Y.; Himeno, M. Lysosomal cysteine protease, cathepsin B, is targeted to lysosomes by the mannose 6-phosphate-independent pathway in rat hepatocytes: Site-specific phosphorylation in oligosaccharides of the proregion. *J. Biochem.* **2000**, *128*, 39–48. [CrossRef]

46. Boonen, M.; Staudt, C.; Gilis, F.; Oorschot, V.; Klumperman, J.; Jadot, M. Cathepsin D and its newly identified transport receptor SEZ6L2 can modulate neurite outgrowth. *J. Cell Sci.* **2016**, *129*, 557–568. [CrossRef]

47. Bright, N.A.; Davis, L.J.; Luzio, J.P. Endolysosomes Are the Principal Intracellular Sites of Acid Hydrolase Activity. *Curr. Biol.* **2016**, *26*, 2233–2245. [CrossRef] [PubMed]

48. Creasy, B.M.; McCoy, K.L. Cytokines regulate cysteine cathepsins during TLR responses. *Cell. Immunol.* **2011**, *267*, 56–66. [CrossRef] [PubMed]

49. Bird, P.I.; Trapani, J.A.; Villadangos, J.A. Endolysosomal proteases and their inhibitors in immunity. *Nat. Rev. Immunol.* **2009**, *9*, 871–882. [CrossRef] [PubMed]

50. Guncar, G.; Pungercic, G.; Klemencic, I.; Turk, V.; Turk, D. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. *EMBO J.* **1999**, *18*, 793–803. [CrossRef]

51. Deussing, J.; Roth, W.; Saftig, P.; Peters, C.; Ploegh, H.L.; Villadangos, J.A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 4516–4521. [CrossRef]

52. Ward, C.; Martinez-Lopez, N.; Otten, E.G.; Carroll, B.; Maetzel, D.; Singh, R.; Sarkar, S.; Korolchuk, V.I. Autophagy, lipophagy and lysosomal lipid storage disorders. *Biochim. Biophys. Acta* **2016**, *1861*, 269–284. [CrossRef]

53. Dennemarker, J.; Lohmuller, T.; Muller, S.; Aguilar, S.V.; Tobin, D.J.; Peters, C.; Reinheckel, T. Impaired turnover of autophagolysosomes in cathepsin L deficiency. *Biol. Chem.* **2010**, *391*, 913–922. [CrossRef]

54. Man, S.M.; Kanneganti, T.D. Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B. *Autophagy* **2016**, *12*, 2504–2505. [CrossRef]

55. Yang, M.; Liu, J.; Shao, J.; Qin, Y.; Ji, Q.; Zhang, X.; Du, J. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. *Mol. Cancer* **2014**, *13*, 43. [CrossRef] [PubMed]

56. Authier, F.; Kouach, M.; Briand, G. Endosomal proteolysis of insulin-like growth factor-I at its C-terminal D-domain by cathepsin B. *FEBS Lett.* **2005**, *579*, 4309–4316. [CrossRef]

57. Guha, S.; Padh, H. Cathepsins: Fundamental effectors of endolysosomal proteolysis. *Indian J. Biochem. Biophys.* **2008**, *45*, 75–90.

58. Kovsan, J.; Ben-Romano, R.; Souza, S.C.; Greenberg, A.S.; Rudich, A. Regulation of adipocyte lipolysis by degradation of the perilipin protein: Nelfinavir enhances lysosome-mediated perilipin proteolysis. *J. Biol. Chem.* **2007**, *282*, 21704–21711. [CrossRef] [PubMed]

59. Robker, R.L.; Russell, D.L.; Espey, L.L.; Lydon, J.P.; O'Malley, B.W.; Richards, J.S. Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 4689–4694. [CrossRef]

60. Follo, C.; Ozzano, M.; Mugoni, V.; Castino, R.; Santoro, M.; Isidoro, C. Knock-down of cathepsin D affects the retinal pigment epithelium, impairs swim-bladder ontogenesis and causes premature death in zebrafish. *PLoS ONE* **2011**, *6*, e21908. [CrossRef] [PubMed]

61. Saftig, P.; Hetman, M.; Schmahl, W.; Weber, K.; Heine, L.; Mossmann, H.; Koster, A.; Hess, B.; Evers, M.; von Figura, K.; et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. *EMBO J.* **1995**, *14*, 3599–3608. [CrossRef]

62. Felbor, U.; Kessler, B.; Mothes, W.; Goebel, H.H.; Ploegh, H.L.; Bronson, R.T.; Olsen, B.R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 7883–7888. [CrossRef]

63. Ketterer, S.; Gomez-Auli, A.; Hillebrand, L.E.; Petrera, A.; Ketscher, A.; Reinheckel, T. Inherited diseases caused by mutations in cathepsin protease genes. *FEBS J.* **2017**, *284*, 1437–1454. [CrossRef]

64. Siintola, E.; Partanen, S.; Stromme, P.; Haapanen, A.; Haltia, M.; Maehlen, J.; Lehesjoki, A.E.; Tyynela, J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. *Brain* **2006**, *129*, 1438–1445. [CrossRef] [PubMed]

65. Hart, T.C.; Hart, P.S.; Bowden, D.W.; Michalec, M.D.; Callison, S.A.; Walker, S.J.; Zhang, Y.Z.; Firatli, E. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. *J. Med. Genet.* **1999**, *36*, 881–887.

66. Ho, N.; Punturieri, A.; Wilkin, D.; Szabo, J.; Johnson, M.; Whaley, J.; Davis, J.; Clark, A.; Weiss, S.; Francomano, C. Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. *J. Bone Min. Res.* **1999**, *14*, 1649–1653. [CrossRef] [PubMed]

67. Mizunoe, Y.; Sudo, Y.; Okita, N.; Hiraoka, H.; Mikami, K.; Narahara, T.; Negishi, A.; Yoshida, M.; Higashibata, R.; Watanabe, S.; et al. Involvement of lysosomal dysfunction in autophagosome accumulation and early pathologies in adipose tissue of obese mice. *Autophagy* **2017**, *13*, 642–653. [CrossRef] [PubMed]

68. Tatti, M.; Motta, M.; Di Bartolomeo, S.; Scarpa, S.; Cianfanelli, V.; Cecconi, F.; Salvioli, R. Reduced cathepsins B and D cause impaired autophagic degradation that can be almost completely restored by overexpression of these two proteases in Sap C-deficient fibroblasts. *Hum. Mol. Genet.* **2012**, *21*, 5159–5173. [CrossRef] [PubMed]

69. McGlinchey, R.P.; Lee, J.C. Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 9322–9327. [CrossRef] [PubMed]

70. Carnevali, O.; Cionna, C.; Tosti, L.; Lubzens, E.; Maradonna, F. Role of cathepsins in ovarian follicle growth and maturation. *Gen. Comp. Endocrinol.* **2006**, *146*, 195–203. [CrossRef]

71. Tsukuba, T.; Yamamoto, K. [Atopic dermatitis and cathepsin E]. *Nihon Yakurigaku Zasshi* **2003**, *122*, 15–20. [CrossRef]

72. Adkison, A.M.; Raptis, S.Z.; Kelley, D.G.; Pham, C.T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. *J. Clin. Investig.* **2002**, *109*, 363–371. [CrossRef]

73. Hao, L.; Zhu, G.; Lu, Y.; Wang, M.; Jules, J.; Zhou, X.; Chen, W. Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role. *FEBS Lett.* **2015**, *589*, 1331–1339. [CrossRef]

74. Ho, C.M.; Ho, S.L.; Jeng, Y.M.; Lai, Y.S.; Chen, Y.H.; Lu, S.C.; Chen, H.L.; Chang, P.Y.; Hu, R.H.; Lee, P.H. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease. *J. Inflamm. (Lond.)* **2019**, *16*, 7. [CrossRef]

75. Kos, J.; Jevnikar, Z.; Obermajer, N. The role of cathepsin X in cell signaling. *Cell Adhes. Migr.* **2009**, *3*, 164–166. [CrossRef] [PubMed]

76. Kiuchi, S.; Tomaru, U.; Ishizu, A.; Imagawa, M.; Kiuchi, T.; Iwasaki, S.; Suzuki, A.; Otsuka, N.; Deguchi, T.; Shimizu, T.; et al. Expression of cathepsins V and S in thymic epithelial tumors. *Hum. Pathol.* **2017**, *60*, 66–74. [CrossRef] [PubMed]

77. Wex, T.; Buhling, F.; Wex, H.; Gunther, D.; Malfertheiner, P.; Weber, E.; Bromme, D. Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. *J. Immunol.* **2001**, *167*, 2172–2178. [CrossRef] [PubMed]

78. Santamaria, I.; Velasco, G.; Pendas, A.M.; Fueyo, A.; Lopez-Otin, C. Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location. *J. Biol. Chem.* **1998**, *273*, 16816–16823. [CrossRef] [PubMed]

79. Carlsson, S.R.; Roth, J.; Piller, F.; Fukuda, M. Isolation and Characterization of Human Lysosomal Membrane-Glycoproteins, H-Lamp-1 and H-Lamp-2-Major Sialoglycoproteins Carrying Polylactosaminoglycan. *J. Biol. Chem.* **1988**, *263*, 18911–18919. [PubMed]

80. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. *Oncogene* **2008**, *27*, 6434–6451. [CrossRef] [PubMed]

81. Kurz, T.; Terman, A.; Gustafsson, B.; Brunk, U.T. Lysosomes in iron metabolism, ageing and apoptosis. *Histochem. Cell Biol.* **2008**, *129*, 389–406. [CrossRef]

82. Kowanko, I.C.; Ferrante, A. Stimulation of neutrophil respiratory burst and lysosomal enzyme release by human interferon-gamma. *Immunology* **1987**, *62*, 149–151.

83. Hoppe, G.; O'Neil, J.; Hoff, H.F.; Sears, J. Products of lipid peroxidation induce missorting of the principal lysosomal protease in retinal pigment epithelium. *Biochim. Biophys. Acta* **2004**, *1689*, 33–41. [CrossRef]

84. Yuan, X.M.; Li, W.; Olsson, A.G.; Brunk, U.T. The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage. *Atherosclerosis* **1997**, *133*, 153–161. [CrossRef]

85. Turrens, J.F. Mitochondrial formation of reactive oxygen species. *J. Physiol.* **2003**, *552*, 335–344. [CrossRef] [PubMed]

86. Aits, S.; Jaattela, M. Lysosomal cell death at a glance. *J. Cell Sci.* **2013**, *126*, 1905–1912. [CrossRef] [PubMed]

87. Miller, D.K.; Griffiths, E.; Lenard, J.; Firestone, R.A. Cell killing by lysosomotropic detergents. *J. Cell Biol.* **1983**, *97*, 1841–1851. [CrossRef]

88. Deamera, D.W.; Bramhall, J. Permeability of lipid bilayers to water and ionic solutes. In *Chemistry and Physics of Lipids*; Elsevier Scientific Publishers Ireland Ltd.: Shannon, Ireland, 1986; Volume 40, pp. 167–188.

89. Deng, D.; Jiang, N.; Hao, S.J.; Sun, H.; Zhang, G.J. Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. *Biochim. Biophys. Acta* **2009**, *1788*, 470–476. [CrossRef]

90. Yi, Y.P.; Wang, X.; Zhang, G.; Fu, T.S.; Zhang, G.J. Phosphatidic acid osmotically destabilizes lysosomes through increased permeability to K+ and H+. *Gen. Physiol. Biophys.* **2006**, *25*, 149–160. [PubMed]

91. Goulet, B.; Baruch, A.; Moon, N.S.; Poirier, M.; Sansregret, L.L.; Erickson, A.; Bogyo, M.; Nepveu, A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. *Mol. Cell* **2004**, *14*, 207–219. [CrossRef]

92. Muntener, K.; Zwicky, R.; Csucs, G.; Rohrer, J.; Baici, A. Exon skipping of cathepsin B: Mitochondrial targeting of a lysosomal peptidase provokes cell death. *J. Biol. Chem.* **2004**, *279*, 41012–41017. [CrossRef]

93. Bestvater, F.; Dallner, C.; Spiess, E. The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability. *BMC Cell Biol.* **2005**, *6*, 16. [CrossRef]

94. Elmore, S. Apoptosis: A review of programmed cell death. *Toxicol. Pathol.* **2007**, *35*, 495–516. [CrossRef]

95. Gupta, S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. *Life Sci.* **2001**, *69*, 2957–2964. [CrossRef]

96. Chwieralski, C.E.; Welte, T.; Buhling, F. Cathepsin-regulated apoptosis. *Apoptosis* **2006**, *11*, 143–149. [CrossRef] [PubMed]

97. Droga-Mazovec, G.; Bojic, L.; Petelin, A.; Ivanova, S.; Romih, R.; Repnik, U.; Salvesen, G.S.; Stoka, V.; Turk, V.; Turk, B. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. *J. Biol. Chem.* **2008**, *283*, 19140–19150. [CrossRef] [PubMed]

98. Conus, S.; Perozzo, R.; Reinheckel, T.; Peters, C.; Scapozza, L.; Yousefi, S.; Simon, H.U. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. *J. Exp. Med.* **2008**, *205*, 685–698. [CrossRef] [PubMed]

99. Bidere, N.; Lorenzo, H.K.; Carmona, S.; Laforge, M.; Harper, F.; Dumont, C.; Senik, A. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. *J. Biol. Chem.* **2003**, *278*, 31401–31411. [CrossRef]

100. Johansson, A.C.; Steen, H.; Ollinger, K.; Roberg, K. Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporine. *Cell Death Differ.* **2003**, *10*, 1253–1259. [CrossRef]

101. McComb, S.; Shutinoski, B.; Thurston, S.; Cessford, E.; Kumar, K.; Sad, S. Cathepsins Limit Macrophage Necroptosis through Cleavage of Rip1 Kinase. *J. Immunol.* **2014**, *192*, 5671–5678. [CrossRef]

102. Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. *Int. J. Mol. Sci.* **2019**, *20*, 3328. [CrossRef]

103. Campden, R.I.; Zhang, Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. *Arch. Biochem. Biophys.* **2019**, *670*, 32–42. [CrossRef]

104. Li, S.L.; Du, L.L.; Zhang, L.; Hu, Y.; Xia, W.C.; Wu, J.; Zhu, J.; Chen, L.L.; Zhu, F.Q.; Li, C.X.; et al. Cathepsin B Contributes to Autophagy-related 7 (Atg7)-induced Nod-like Receptor 3 (NLRP3)-dependent Proinflammatory Response and Aggravates Lipotoxicity in Rat Insulinoma Cell Line. *J. Biol. Chem.* **2013**, *288*, 30094–30104. [CrossRef]

105. Niemi, K.; Teirila, L.; Lappalainen, J.; Rajamaki, K.; Baumann, M.H.; Oorni, K.; Wolff, H.; Kovanen, P.T.; Matikainen, S.; Eklund, K.K. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. *J. Immunol.* **2011**, *186*, 6119–6128. [CrossRef]

106. Orlowski, G.M.; Colbert, J.D.; Sharma, S.; Bogyo, M.; Robertson, S.A.; Rock, K.L. Multiple Cathepsins Promote Pro-IL-1beta Synthesis and NLRP3-Mediated IL-1beta Activation. *J. Immunol.* **2015**, *195*, 1685–1697. [CrossRef] [PubMed]

107. Soond, S.M.; Kozhevnikova, M.V.; Frolova, A.S.; Savvateeva, L.V.; Plotnikov, E.Y.; Townsend, P.A.; Han, Y.P.; Zamyatnin, A.A., Jr. Lost or Forgotten: The nuclear cathepsin protein isoforms in cancer. *Cancer Lett.* **2019**, *462*, 43–50. [CrossRef]

108. Tamhane, T.; Illukkumbura, R.; Lu, S.Y.; Maelandsmo, G.M.; Haugen, M.H.; Brix, K. Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells. *Biochimie* **2016**, *122*, 208–218. [CrossRef] [PubMed]

109. Bach, A.S.; Derocq, D.; Laurent-Matha, V.; Montcourrier, P.; Sebti, S.; Orsetti, B.; Theillet, C.; Gongora, C.; Pattingre, S.; Ibing, E.; et al. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. *Oncotarget* **2015**, *6*, 28084–28103. [CrossRef] [PubMed]

110. Zhang, X.; Zhou, Y.; Yu, X.; Huang, Q.; Fang, W.; Li, J.; Bonventre, J.V.; Sukhova, G.K.; Libby, P.; Shi, G.P. Differential Roles of Cysteinyl Cathepsins in TGF-beta Signaling and Tissue Fibrosis. *iScience* **2019**, *19*, 607–622. [CrossRef]

111. Leist, M.; Jaattela, M. Triggering of apoptosis by cathepsins. *Cell Death Differ.* **2001**, *8*, 324–326. [CrossRef]

112. Thibeaux, S.; Siddiqi, S.; Zhelyabovska, O.; Moinuddin, F.; Masternak, M.M.; Siddiqi, S.A. Cathepsin B regulates hepatic lipid metabolism by cleaving liver fatty acid-binding protein. *J. Biol. Chem.* **2018**, *293*, 1910–1923. [CrossRef]

113. Roberts, L.R.; Kurosawa, H.; Bronk, S.F.; Fesmier, P.J.; Agellon, L.B.; Leung, W.Y.; Mao, F.; Gores, G.J. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. *Gastroenterology* **1997**, *113*, 1714–1726. [CrossRef]

114. Agostini, M.; Tucci, P.; Melino, G. Cell death pathology: Perspective for human diseases. *Biochem. Biophys. Res. Commun.* **2011**, *414*, 451–455. [CrossRef] [PubMed]

115. Mattson, M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. *Antioxid. Redox Signal.* **2006**, *8*, 1997–2006. [CrossRef]

116. Lin, Y.; Epstein, D.L.; Liton, P.B. Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress. *Investig. Ophthalmol. Vis. Sci.* **2010**, *51*, 6483–6495. [CrossRef] [PubMed]

117. Sato, Y.; Suzuki, Y.; Ito, E.; Shimazaki, S.; Ishida, M.; Yamamoto, T.; Yamamoto, H.; Toda, T.; Suzuki, M.; Suzuki, A.; et al. Identification and characterization of an increased glycoprotein in aging: Age-associated translocation of cathepsin D. *Mech. Ageing Dev.* **2006**, *127*, 771–778. [CrossRef] [PubMed]

118. Jung, H.; Lee, E.Y.; Lee, S.I. Age-related changes in ultrastructural features of cathepsin B- and D-containing neurons in rat cerebral cortex. *Brain Res.* **1999**, *844*, 43–54. [CrossRef]

119. Yu, J.W.; Lee, M.S. Mitochondria and the NLRP3 inflammasome: Physiological and pathological relevance. *Arch. Pharm. Res.* **2016**, *39*, 1503–1518. [CrossRef]

120. Cocchiaro, P.; De Pasquale, V.; Della Morte, R.; Tafuri, S.; Avallone, L.; Pizard, A.; Moles, A.; Pavone, L.M. The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease. *Front. Cell Dev. Biol.* **2017**, *5*, 114. [CrossRef]

121. Sever, S.; Altintas, M.M.; Nankoe, S.R.; Moller, C.C.; Ko, D.; Wei, C.L.; Henderson, J.; del Re, E.C.; Hsing, L.; Erickson, A.; et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. *J. Clin. Investig.* **2007**, *117*, 2095–2104. [CrossRef]

122. Maubach, G.; Lim, M.C.; Zhuo, L. Nuclear cathepsin F regulates activation markers in rat hepatic stellate cells. *Mol. Biol. Cell* **2008**, *19*, 4238–4248. [CrossRef]

123. Baici, A.; Muntener, K.; Willimann, A.; Zwicky, R. Regulation of human cathepsin B by alternative mRNA splicing: Homeostasis, fatal errors and cell death. *Biol. Chem.* **2006**, *387*, 1017–1021. [CrossRef]

124. Olson, O.C.; Joyce, J.A. Cysteine cathepsin proteases: Regulators of cancer progression and therapeutic response. *Nat. Rev. Cancer* **2015**, *15*, 712–729. [CrossRef]

125. Samie, M.A.; Xu, H. Lysosomal exocytosis and lipid storage disorders. *J. Lipid Res.* **2014**, *55*, 995–1009. [CrossRef]

126. Guardia, C.M.; Farias, G.G.; Jia, R.; Pu, J.; Bonifacino, J.S. BORC Functions Upstream of Kinesins 1 and 3 to Coordinate Regional Movement of Lysosomes along Different Microtubule Tracks. *Cell Rep.* **2016**, *17*, 1950–1961. [CrossRef] [PubMed]

127. Rao, S.K.; Huynh, C.; Proux-Gillardeaux, V.; Galli, T.; Andrews, N.W. Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis. *J. Biol. Chem.* **2004**, *279*, 20471–20479. [CrossRef] [PubMed]

128. Medina, D.L.; Fraldi, A.; Bouche, V.; Annunziata, F.; Mansueto, G.; Spampanato, C.; Puri, C.; Pignata, A.; Martina, J.A.; Sardiello, M.; et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. *Dev. Cell* **2011**, *21*, 421–430. [CrossRef] [PubMed]

129. Castro-Gomes, T.; Corrotte, M.; Tam, C.; Andrews, N.W. Plasma Membrane Repair Is Regulated Extracellularly by Proteases Released from Lysosomes. *PLoS ONE* **2016**, *11*, e0152583. [CrossRef]

130. Olson, L.J.; Hindsgaul, O.; Dahms, N.M.; Kim, J.J. Structural insights into the mechanism of pH-dependent ligand binding and release by the cation-dependent mannose 6-phosphate receptor. *J. Biol. Chem.* **2008**, *283*, 10124–10134. [CrossRef]

131. Jane, D.T.; Morvay, L.; DaSilva, L.; Cavallo-Medved, D.; Sloane, B.F.; Dufresne, M.J. Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH. *Biol. Chem.* **2006**, *387*, 223–234. [CrossRef]

132. Jordans, S.; Jenko-Kokalj, S.; Kuhl, N.M.; Tedelind, S.; Sendt, W.; Bromme, D.; Turk, D.; Brix, K. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. *BMC Biochem.* **2009**, *10*. [CrossRef]

133. Uhlman, A.; Folkers, K.; Liston, J.; Pancholi, H.; Hinton, A. Effects of Vacuolar H(+)-ATPase Inhibition on Activation of Cathepsin B and Cathepsin L Secreted from MDA-MB231 Breast Cancer Cells. *Cancer Microenviron.* **2017**, *10*, 49–56. [CrossRef]

134. Yang, D.Q.; Feng, S.; Chen, W.; Zhao, H.; Paulson, C.; Li, Y.P. V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast-mediated bone resorption. *J. Bone Min. Res.* **2012**, *27*, 1695–1707. [CrossRef]

135. Runger, T.M.; Quintanilla-Dieck, M.J.; Bhawan, J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. *J. Investig. Derm.* **2007**, *127*, 293–297. [CrossRef]

136. Goto, T.; Yamaza, T.; Tanaka, T. Cathepsins in the osteoclast. *J. Electron. Microsc. (Tokyo)* **2003**, *52*, 551–558. [CrossRef]

137. Saftig, P.; Hunziker, E.; Everts, V.; Jones, S.; Boyde, A.; Wehmeyer, O.; Suter, A.; von Figura, K. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. *Adv. Exp. Med. Biol.* **2000**, *477*, 293–303. [CrossRef]

138. Bonnans, C.; Chou, J.; Werb, Z. Remodelling the extracellular matrix in development and disease. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 786–801. [CrossRef]

139. Fonovic, M.; Turk, B. Cysteine cathepsins and extracellular matrix degradation. *Biochim. Biophys. Acta* **2014**, *1840*, 2560–2570. [CrossRef] [PubMed]

140. Raggatt, L.J.; Partridge, N.C. Cellular and molecular mechanisms of bone remodeling. *J. Biol. Chem.* **2010**, *285*, 25103–25108. [CrossRef]

141. Troen, B.R. The role of cathepsin K in normal bone resorption. *Drug News Perspect.* **2004**, *17*, 19–28. [CrossRef] [PubMed]

142. Page, A.E.; Hayman, A.R.; Andersson, L.M.B.; Chambers, T.J.; Warburton, M.J. Degradation of Bone-Matrix Proteins by Osteoclast Cathepsins. *Int. J. Biochem.* **1993**, *25*, 545–550. [CrossRef]

143. Saini, M.G.; Bix, G.J. Oxygen-glucose deprivation (OGD) and interleukin-1 (IL-1) differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. *Brain Res.* **2012**, *1438*, 65–74. [CrossRef] [PubMed]

144. Roberts, J.; Kahle, M.P.; Bix, G.J. Perlecan and the blood-brain barrier: Beneficial proteolysis? *Front. Pharm.* **2012**, *3*, 155. [CrossRef]

145. Buth, H.; Luigi Buttigieg, P.; Ostafe, R.; Rehders, M.; Dannenmann, S.R.; Schaschke, N.; Stark, H.J.; Boukamp, P.; Brix, K. Cathepsin B is essential for regeneration of scratch-wounded normal human epidermal keratinocytes. *Eur. J. Cell Biol.* **2007**, *86*, 747–761. [CrossRef]

146. Obermajer, N.; Repnik, U.; Jevnikar, Z.; Turk, B.; Kreft, M.; Kos, J. Cysteine protease cathepsin X modulates immune response via activation of beta2 integrins. *Immunology* **2008**, *124*, 76–88. [CrossRef] [PubMed]

147. Hook, V.; Yasothornsrikul, S.; Greenbaum, D.; Medzihradszky, K.F.; Troutner, K.; Toneff, T.; Bundey, R.; Logrinova, A.; Reinheckel, T.; Peters, C.; et al. Cathepsin L and Arg/Lys aminopeptidase: A distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. *Biol. Chem.* **2004**, *385*, 473–480. [CrossRef] [PubMed]

148. Funkelstein, L.; Lu, W.D.; Koch, B.; Mosier, C.; Toneff, T.; Taupenot, L.; O'Connor, D.T.; Reinheckel, T.; Peters, C.; Hook, V. Human cathepsin V protease participates in production of enkephalin and NPY neuropeptide neurotransmitters. *J. Biol. Chem.* **2012**, *287*, 15232–15241. [CrossRef] [PubMed]

149. Hwang, S.R.; Garza, C.; Mosier, C.; Toneff, T.; Wunderlich, E.; Goldsmith, P.; Hook, V. Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion. *J. Biol. Chem.* **2007**, *282*, 9556–9563. [CrossRef]

150. Yasothornsrikul, S.; Greenbaum, D.; Medzihradszky, K.F.; Toneff, T.; Bundey, R.; Miller, R.; Schilling, B.; Petermann, I.; Dehnert, J.; Logvinova, A.; et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 9590–9595. [CrossRef]

151. Yan, D.; Wang, H.W.; Bowman, R.L.; Joyce, J.A. STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1alpha Activation. *Cell Rep.* **2016**, *16*, 2914–2927. [CrossRef]

152. Sloane, B.F.; Yan, S.; Podgorski, I.; Linebaugh, B.E.; Cher, M.L.; Mai, J.; Cavallo-Medved, D.; Sameni, M.; Dosescu, J.; Moin, K. Cathepsin B and tumor proteolysis: Contribution of the tumor microenvironment. *Semin. Cancer Biol.* **2005**, *15*, 149–157. [CrossRef]

153. Hashimoto, Y.; Kondo, C.; Katunuma, N. An Active 32-kDa Cathepsin L Is Secreted Directly from HT 1080 Fibrosarcoma Cells and Not via Lysosomal Exocytosis. *PLoS ONE* **2015**, *10*, e0145067. [CrossRef]

154. Nicotra, G.; Castino, R.; Follo, C.; Peracchio, C.; Valente, G.; Isidoro, C. The dilemma: Does tissue expression of cathepsin D reflect tumor malignancy? The question: Does the assay truly mirror cathepsin D mis-function in the tumor? *Cancer Biomark.* **2010**, *7*, 47–64. [CrossRef]

155. Gocheva, V.; Zeng, W.; Ke, D.; Klimstra, D.; Reinheckel, T.; Peters, C.; Hanahan, D.; Joyce, J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. *Genes Dev.* **2006**, *20*, 543–556. [CrossRef]

156. Lkhider, M.; Castino, R.; Bouguyon, E.; Isidoro, C.; Ollivier-Bousquet, M. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. *J. Cell Sci.* **2004**, *117*, 5155–5164. [CrossRef]

157. Erdmann, S.; Ricken, A.; Merkwitz, C.; Struman, I.; Castino, R.; Hummitzsch, K.; Gaunitz, F.; Isidoro, C.; Martial, J.; Spanel-Borowski, K. The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *293*, E1365–E1377. [CrossRef]

158. Sobotic, B.; Vizovisek, M.; Vidmar, R.; Van Damme, P.; Gocheva, V.; Joyce, J.A.; Gevaert, K.; Turk, V.; Turk, B.; Fonovic, M. Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. *Mol. Cell Proteom.* **2015**, *14*, 2213–2228. [CrossRef] [PubMed]

159. Mizunoe, Y.; Kobayashi, M.; Tagawa, R.; Nakagawa, Y.; Shimano, H.; Higami, Y. Association between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome. *Int. J. Mol. Sci.* **2019**, *20*, 3688. [CrossRef] [PubMed]

160. Bourne, L.C.; Lamb, D.J.; Collis, C.S.; O'Brien, M.; Leake, D.S.; Rice-Evans, C. Non-oxidative modification of low density lipoprotein by ruptured myocytes. *FEBS Lett.* **1997**, *414*, 576–580. [CrossRef]

161. Benes, P.; Vetvicka, V.; Fusek, M. Cathepsin D—Many functions of one aspartic protease. *Crit. Rev. Oncol. Hematol.* **2008**, *68*, 12–28. [CrossRef] [PubMed]

162. Khurana, P.; Yadati, T.; Goyal, S.; Dolas, A.; Houben, T.; Oligschlaeger, Y.; Agarwal, A.K.; Kulkarni, A.; Shiri-Sverdlov, R. Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague(-)Dawley Rats (dagger). *Biomolecules* **2019**, *9*, 171. [CrossRef]

163. Zhao, C.F.; Herrington, D.M. The function of cathepsins B, D, and X in atherosclerosis. *Am. J. Cardiovasc. Dis.* **2016**, *6*, 163–170.

164. Wiener, J.J.; Sun, S.; Thurmond, R.L. Recent advances in the design of cathepsin S inhibitors. *Curr. Top. Med. Chem.* **2010**, *10*, 717–732. [CrossRef]

165. Maciewicz, R.A.; Wotton, S.F. Degradation of cartilage matrix components by the cysteine proteinases, cathepsins B and L. *Biomed. Biochim. Acta* **1991**, *50*, 561–564.

166. Buck, M.R.; Karustis, D.G.; Day, N.A.; Honn, K.V.; Sloane, B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. *Biochem. J.* **1992**, *282 Pt 1*, 273–278. [CrossRef]

167. Ishidoh, K.; Kominami, E. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. *Biochem. Biophys. Res. Commun.* **1995**, *217*, 624–631. [CrossRef] [PubMed]

168. Wang, B.; Sun, J.; Kitamoto, S.; Yang, M.; Grubb, A.; Chapman, H.A.; Kalluri, R.; Shi, G.P. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. *J. Biol. Chem.* **2006**, *281*, 6020–6029. [CrossRef] [PubMed]

169. Son, E.D.; Kim, H.; Choi, H.; Lee, S.H.; Lee, J.Y.; Kim, S.; Closs, B.; Lee, S.; Chung, J.H.; Hwang, J.S. Cathepsin G increases MMP expression in normal human fibroblasts through fibronectin fragmentation, and induces the conversion of proMMP-1 to active MMP-1. *J. Derm. Sci.* **2009**, *53*, 150–152. [CrossRef] [PubMed]

170. Mai, J.; Sameni, M.; Mikkelsen, T.; Sloane, B.F. Degradation of extracellular matrix protein tenascin-C by cathepsin B: An interaction involved in the progression of gliomas. *Biol. Chem.* **2002**, *383*, 1407–1413. [CrossRef] [PubMed]

171. Mort, J.S.; Magny, M.C.; Lee, E.R. Cathepsin B: An alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. *Biochem. J.* **1998**, *335 Pt 3*, 491–494. [CrossRef]

172. Garcia, M.; Platet, N.; Liaudet, E.; Laurent, V.; Derocq, D.; Brouillet, J.P.; Rochefort, H. Biological and clinical significance of cathepsin D in breast cancer metastasis. *Stem Cells* **1996**, *14*, 642–650. [CrossRef]

173. Du, X.; Chen, N.L.; Wong, A.; Craik, C.S.; Bromme, D. Elastin degradation by cathepsin V requires two exosites. *J. Biol. Chem.* **2013**, *288*, 34871–34881. [CrossRef]

174. Staudt, N.D.; Aicher, W.K.; Kalbacher, H.; Stevanovic, S.; Carmona, A.K.; Bogyo, M.; Klein, G. Cathepsin X is secreted by human osteoblasts, digests CXCL-12 and impairs adhesion of hematopoietic stem and progenitor cells to osteoblasts. *Haematologica* **2010**, *95*, 1452–1460. [CrossRef]

175. Ondr, J.K.; Pham, C.T. Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity. *J. Biol. Chem.* **2004**, *279*, 27525–27533. [CrossRef]

176. Fonovic, M.; Turk, B. Cysteine cathepsins and their potential in clinical therapy and biomarker discovery. *Proteom. Clin. Appl.* **2014**, *8*, 416–426. [CrossRef]

177. Joyce, J.A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F.Y.; Greenbaum, D.C.; Hager, J.H.; Bogyo, M.; Hanahan, D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. *Cancer Cell* **2004**, *5*, 443–453. [CrossRef]

178. Gabrijelcic, D.; Svetic, B.; Spaic, D.; Skrk, J.; Budihna, M.; Dolenc, I.; Popovic, T.; Cotic, V.; Turk, V. Cathepsins B, H and L in human breast carcinoma. *Eur. J. Clin. Chem. Clin. Biochem.* **1992**, *30*, 69–74.

179. Hashimoto, Y.; Kondo, C.; Kojima, T.; Nagata, H.; Moriyama, A.; Hayakawa, T.; Katunuma, N. Significance of 32-kDa cathepsin L secreted from cancer cells. *Cancer Biother. Radiopharm.* **2006**, *21*, 217–224. [CrossRef]

180. Singh, N.; Das, P.; Gupta, S.; Sachdev, V.; Srivasatava, S.; Datta Gupta, S.; Pandey, R.M.; Sahni, P.; Chauhan, S.S.; Saraya, A. Plasma cathepsin L: A prognostic marker for pancreatic cancer. *World J. Gastroenterol.* **2014**, *20*, 17532–17540. [CrossRef] [PubMed]

181. Ruan, J.; Zheng, H.; Fu, W.; Zhao, P.; Su, N.; Luo, R. Increased expression of cathepsin L: A novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients. *PLoS ONE* **2014**, *9*, e112136. [CrossRef]

182. Schweiger, A.; Staib, A.; Werle, B.; Krasovec, M.; Lah, T.T.; Ebert, W.; Turk, V.; Kos, J. Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: Relation to prognosis and cigarette smoking. *Br. J. Cancer* **2000**, *82*, 782–788. [CrossRef] [PubMed]

183. Kos, J.; Stabuc, B.; Schweiger, A.; Krasovec, M.; Cimerman, N.; KopitarJerala, N.; Vrhovec, I. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. *Clin. Cancer Res.* **1997**, *3*, 1815–1822. [PubMed]

184. Schweiger, A.; Christensen, I.J.; Nielsen, H.J.; Sorensen, S.; Brunner, N.; Kos, J. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. *Int. J. Biol. Markers* **2004**, *19*, 289–294. [CrossRef]

185. Kos, J.; Werle, B.; Lah, T.; Brunner, N. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. *Int. J. Biol. Markers* **2000**, *15*, 84–89. [CrossRef] [PubMed]

186. Wu, H.; Du, Q.; Dai, Q.; Ge, J.; Cheng, X. Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases. *J. Atheroscler. Thromb.* **2018**, *25*, 111–123. [CrossRef] [PubMed]

187. Walenbergh, S.M.; Houben, T.; Rensen, S.S.; Bieghs, V.; Hendrikx, T.; van Gorp, P.J.; Oligschlaeger, Y.; Jeurissen, M.L.; Gijbels, M.J.; Buurman, W.A.; et al. Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. *Sci. Rep.* **2016**, *6*, 38278. [CrossRef] [PubMed]

188. Liu, L.; Chen, B.; Zhang, X.; Tan, L.; Wang, D.W. Increased Cathepsin D Correlates with Clinical Parameters in Newly Diagnosed Type 2 Diabetes. *Dis. Markers* **2017**, *2017*, 5286408. [CrossRef] [PubMed]

189. Ding, L.L.; Goossens, G.H.; Oligschlaeger, Y.; Houben, T.; Blaak, E.E.; Shiri-Sverdlov, R. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. *Diabetologia* **2019**. [CrossRef]

190. Dera, A.A.; Ranganath, L.; Barraclough, R.; Vinjamuri, S.; Hamill, S.; Barraclough, D.L. Cathepsin Z as a novel potential biomarker for osteoporosis. *Sci. Rep.* **2019**, 9. [CrossRef]

191. Wang, L.; Hu, Y.Q.; Zhao, Z.J.; Zhang, H.Y.; Gao, B.; Lu, W.G.; Xu, X.L.; Lin, X.S.; Wang, J.P.; Jie, Q.; et al. Screening and validation of serum protein biomarkers for early postmenopausal osteoporosis diagnosis. *Mol. Med. Rep.* **2017**, *16*, 8427–8433. [CrossRef] [PubMed]

192. Kramer, L.; Turk, D.; Turk, B. The Future of Cysteine Cathepsins in Disease Management. *Trends Pharm. Sci.* **2017**, *38*, 873–898. [CrossRef] [PubMed]

193. Marques, A.R.A.; Di Spiezio, A.; Thiessen, N.; Schmidt, L.; Grotzinger, J.; Lullmann-Rauch, R.; Damme, M.; Storck, S.E.; Pietrzik, C.U.; Fogh, J.; et al. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis. *Autophagy* **2020**, *16*, 811–825. [CrossRef]

194. Desnick, R.J.; Schuchman, E.H. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. *Annu. Rev. Genom. Hum. Genet.* **2012**, *13*, 307–335. [CrossRef]

195. Khaket, T.P.; Kwon, T.K.; Kang, S.C. Cathepsins: Potent regulators in carcinogenesis. *Pharm. Ther.* **2019**, *198*, 1–19. [CrossRef]

196. Verbovsek, U.; Van Noorden, C.J.; Lah, T.T. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. *Semin. Cancer Biol.* **2015**, *35*, 71–84. [CrossRef]

197. Mullard, A. Merck & Co. drops osteoporosis drug odanacatib. *Nat. Rev. Drug Discov.* **2016**, *15*, 669. [CrossRef]

198. Panwar, P.; Soe, K.; Guido, R.V.; Bueno, R.V.; Delaisse, J.M.; Bromme, D. A novel approach to inhibit bone resorption: Exosite inhibitors against cathepsin K. *Br. J. Pharm.* **2016**, *173*, 396–410. [CrossRef] [PubMed]

199. Panwar, P.; Xue, L.M.; Soe, K.; Srivastava, K.; Law, S.; Delaisse, J.M.; Bromme, D. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice (vol 32, pg 2415, 2017). *J. Bone Miner. Res.* **2019**, *34*, 777–778. [CrossRef] [PubMed]

200. Burden, R.E.; Gormley, J.A.; Jaquin, T.J.; Small, D.M.; Quinn, D.J.; Hegarty, S.M.; Ward, C.; Walker, B.; Johnston, J.A.; Olwill, S.A.; et al. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. *Clin. Cancer Res.* **2009**, *15*, 6042–6051. [CrossRef]

201. Burden, R.E.; Gormley, J.A.; Kuehn, D.; Ward, C.; Kwok, H.F.; Gazdoiu, M.; McClurg, A.; Jaquin, T.J.; Johnston, J.A.; Scott, C.J.; et al. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. *Biochimie* **2012**, *94*, 487–493. [CrossRef] [PubMed]

202. Mirkovic, B.; Markelc, B.; Butinar, M.; Mitrovic, A.; Sosic, I.; Gobec, S.; Vasiljeva, O.; Turk, B.; Cemazar, M.; Sersa, G.; et al. Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. *Oncotarget* **2015**, *6*, 19027–19042. [CrossRef] [PubMed]

203. Mikhaylov, G.; Klimpel, D.; Schaschke, N.; Mikac, U.; Vizovisek, M.; Fonovic, M.; Turk, V.; Turk, B.; Vasiljeva, O. Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor. *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 10077–10081. [CrossRef] [PubMed]